{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "e13cdc73",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://science.sciencemag.org/content/early/2020/06/19/science.abc6952/tab-pdf\n",
      "https://www.jimmunol.org/content/early/2020/06/23/jimmunol.2000583\n",
      "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1000197\n",
      "https://www.nature.com/articles/s41421-021-00292-z\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1\n",
      "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1002859\n",
      "https://www.sciencedirect.com/science/article/pii/S0042682206006854\n",
      "https://www.pnas.org/content/pnas/111/19/E2018.full.pdf\n",
      "https://academic.oup.com/jid/article/193/5/685/877553\n",
      "https://www.nature.com/articles/s41421-021-00295-w\n",
      "https://www.biorxiv.org/content/10.1101/2020.06.30.178897v1\n",
      "https://www.rcsb.org/structure/7dd2\n",
      "https://www.nature.com/articles/s41423-020-0426-7\n",
      "https://www.nature.com/articles/s41467-020-16256-y\n",
      "https://www.sciencedirect.com/science/article/pii/S2211124720308998\n",
      "https://www.sciencedirect.com/science/article/pii/S2666379121001567\n",
      "https://www.nature.com/articles/cr2015113\n",
      "https://www.sciencedirect.com/science/article/pii/S0165242707000487\n",
      "https://www.biorxiv.org/content/10.1101/2021.05.16.444004v1\n",
      "https://www.biorxiv.org/content/10.1101/2020.11.24.395079v1\n",
      "https://www.rcsb.org/structure/7EAN\n",
      "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0232757;WO2019039891 \n",
      "https://www.rcsb.org/structure/7CR5\n",
      "https://www.nature.com/articles/s41467-019-10897-4\n",
      "https://www.rcsb.org/structure/7EAM\n",
      "https://www.jbc.org/content/281/45/34610.long\n",
      "https://www.biorxiv.org/content/10.1101/2020.12.31.424987v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.02.25.432969v1\n",
      "https://science.sciencemag.org/content/early/2021/06/30/science.abh1766\n",
      "https://www.biorxiv.org/content/10.1101/2021.02.02.429458v1\n",
      "https://www.pnas.org/content/117/47/29832\n",
      "https://academic.oup.com/jid/article/218/8/1249/5017222\n",
      "https://www.biorxiv.org/content/10.1101/2020.08.19.253369v2.full.pdf+html\n",
      "https://www.biorxiv.org/content/10.1101/2021.01.07.425806v1\n",
      "https://cvi.asm.org/content/13/5/594.long\n",
      "https://www.cell.com/cell/fulltext/S0092-8674\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867421002245\n",
      "https://www.sciencedirect.com/science/article/pii/S0006291X05010892\n",
      "https://www.biorxiv.org/content/10.1101/2021.07.05.451203v1\n",
      "https://science.sciencemag.org/content/early/2020/05/12/science.abc2241\n",
      "https://www.nature.com/articles/s41594-021-00596-4\n",
      "https://www.who.int/medicines/publications/druginformation/innlists/PL124-COVID.pdf\n",
      "https://www.biorxiv.org/content/10.1101/2020.07.09.195263v1\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867420306206\n",
      "https://www.nature.com/articles/s41422-021-00555-0\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867421005353\n",
      "https://www.sciencedirect.com/science/article/pii/S2589004221004478\n",
      "https://www.nature.com/articles/s41586-020-2456-9\n",
      "https://www.nature.com/articles/s41586-021-03207-w\n",
      "https://www.nature.com/articles/s41586-021-03696-9\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867421008849\n",
      "https://www.biorxiv.org/content/10.1101/2020.05.13.092619v2\n",
      "https://www.biorxiv.org/content/10.1101/2020.11.13.381533v1\n",
      "https://www.nature.com/articles/s41586-021-03324-6\n",
      "https://www.nature.com/articles/s41586-020-2381-y_reference.pdf\n",
      "https://www.nature.com/articles/s42003-021-02029-w\n",
      "https://www.nature.com/articles/s41467-021-23074-3#Sec18\n",
      "https://science.sciencemag.org/content/early/2020/06/15/science.abc7520\n",
      "https://jvi.asm.org/content/92/10/e02002-17\n",
      "https://science.sciencemag.org/content/early/2021/05/03/science.abg5268\n",
      "https://doi.org/10.1016/j.cell.2020.06.044\n",
      "https://www.biorxiv.org/content/10.1101/2021.01.26.428356v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.05.02.442326v1\n",
      "https://www.nature.com/articles/s41591-020-0998-x\n",
      "https://science.sciencemag.org/content/early/2020/06/15/science.abc5902\n",
      "https://www.sciencedirect.com/science/article/pii/S009286742100221X\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867421004281\n",
      "https://jvi.asm.org/content/79/3/1635\n",
      "https://www.tandfonline.com/doi/full/10.1080/19420862.2021.1922134\n",
      "https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0030237\n",
      "https://www.biorxiv.org/content/10.1101/2021.09.30.462420v1.full\n",
      "https://www.biorxiv.org/content/10.1101/2020.08.15.252320v1.full.pdf\n",
      "https://www.biorxiv.org/content/10.1101/2020.05.12.091298v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.03.23.436684v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.01.437942v1\n",
      "https://www.nature.com/articles/ncomms8712\n",
      "https://www.biorxiv.org/content/10.1101/2021.05.31.446421v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.03.02.433360v1\n",
      "https://www.biorxiv.org/content/10.1101/2020.12.31.424729v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.07.20.453054v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.05.29.443900v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.02.12.430940v1\n",
      "https://www.biorxiv.org/content/10.1101/2020.06.12.148387v1\n",
      "https://www.sciencedirect.com/science/article/pii/S0161589004002548\n",
      "https://www.sciencedirect.com/science/article/pii/S0022283609003374\n",
      "https://www.nature.com/articles/s41467-021-23825-2\n",
      "https://www.sciencedirect.com/science/article/pii/S1931312821001335\n",
      "https://www.nature.com/articles/s41586-020-2571-7\n",
      "https://www.rcsb.org/structure/7KXK\n",
      "https://www.nature.com/articles/s41422-020-00446-w\n",
      "https://www.cell.com/cell-reports/fulltext/S2211-1247\n",
      "https://www.pnas.org/content/114/35/E7348\n",
      "https://onlinelibrary.wiley.com/doi/10.1002/mco2.60\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.07.438849v2\n",
      "https://www.biorxiv.org/content/10.1101/2020.06.02.129098v2\n",
      "https://www.nature.com/articles/s41594-020-0469-6\n",
      "https://www.semanticscholar.org/paper/A-human-neutralizing-antibody-against-a-epitope-by-Duan-Ji/ca990dfe192853fc9fc107398352b16a5c45d39b/figure/2\n",
      "https://academic.oup.com/nsr/article/8/3/nwaa297/6041739\n",
      "https://www.science.org/doi/full/10.1126/scitranslmed.abi7826\n",
      "https://www.researchsquare.com/article/rs-548968/v1\n",
      "https://www.jbc.org/content/295/36/12814.full.pdf\n",
      "https://www.biorxiv.org/content/10.1101/2020.12.29.424711v1\n",
      "https://www.sciencedirect.com/science/article/pii/S2451945621002646\n",
      "https://www.sciencedirect.com/science/article/pii/S0006291X05023417\n",
      "https://www.pnas.org/content/pnas/112/33/10473.full.pdf\n",
      "https://www.biorxiv.org/content/10.1101/2020.06.09.143438v1\n",
      "https://www.sciencedirect.com/science/article/pii/S0166093407002236\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.30.442182v3\n",
      "https://www.biorxiv.org/content/10.1101/2020.09.30.318972v1\n",
      "https://cvi.asm.org/content/13/8/953\n",
      "https://www.nature.com/articles/ncomms9223\n",
      "https://jvi.asm.org/content/88/14/7796\n",
      "https://www.sciencedirect.com/science/article/pii/S0006291X11022984\n",
      "https://www.jbc.org/content/281/23/15829.long\n",
      "https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.79\n",
      "https://science.sciencemag.org/content/early/2020/06/15/science.abc7424\n",
      "https://www.nature.com/articles/s41598-021-88809-0\n",
      "https://www.biorxiv.org/content/10.1101/2020.09.03.280370v1.full\n",
      "https://academic.oup.com/jid/article/215/12/1807/3786458\n",
      "https://www.nature.com/articles/s41467-020-18159-4\n",
      "https://stm.sciencemag.org/content/6/234/234ra59.long\n",
      "https://www.biorxiv.org/content/10.1101/2021.06.04.447066v1\n",
      "https://www.rcsb.org/structure/7DPM\n",
      "https://www.biorxiv.org/content/10.1101/2021.09.14.460356v1\n",
      "https://www.sciencedirect.com/science/article/pii/S1286457907001724\n",
      "https://elifesciences.org/articles/64815\n",
      "https://science.sciencemag.org/content/early/2020/11/04/science.abe3255\n",
      "https://science.sciencemag.org/content/early/2020/11/04/science.abe4747\n",
      "https://www.biorxiv.org/content/10.1101/2020.08.09.242867v1.full.pdf\n",
      "https://www.biorxiv.org/content/10.1101/2020.12.09.417741v1\n",
      "https://www.nature.com/articles/s41467-021-25153-x#Sec34\n",
      "https://www.nature.com/articles/s41598-020-79036-0\n",
      "https://www.embopress.org/doi/full/10.15252/embr.202052325\n",
      "https://pubs.acs.org/doi/10.1021/acs.analchem.1c00677\n",
      "https://www.cell.com/action/showPdf?pii=S1074-7613%2821%2900359-9\n",
      "https://www.sciencedirect.com/science/article/pii/S1074761321001357\n",
      "https://advances.sciencemag.org/content/early/2021/04/22/sciadv.abg7607\n",
      "https://www.nature.com/articles/s41422-020-00444-y\n",
      "https://www.nature.com/articles/s41467-021-24514-w\n",
      "https://www.biorxiv.org/content/10.1101/2020.10.13.336800v1\n",
      "https://www.nature.com/articles/s41586-020-2380-z\n",
      "http://www.rcsb.org/structure/7CJI\n",
      "http://www.rcsb.org/structure/7CDI\n",
      "https://science.sciencemag.org/content/early/2021/08/03/science.abj3321\n",
      "https://www.nature.com/articles/s41467-021-22926-2\n",
      "https://www.sciencedirect.com/science/article/pii/S2211124721012869\n",
      "https://www.biorxiv.org/content/10.1101/2021.01.03.425141v1\n",
      "https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3001209\n",
      "https://www.biorxiv.org/content/10.1101/2021.07.08.451649v1\n",
      "https://www.jbc.org/article/S0021-9258\n",
      "https://www.nature.com/articles/s41594-021-00652-z\n",
      "https://www.researchsquare.com/article/rs-105739/v1\n",
      "https://www.biorxiv.org/content/10.1101/2020.11.11.378778v1\n",
      "https://www.embopress.org/doi/full/10.15252/embj.2021107985\n",
      "https://www.pnas.org/content/112/28/8738\n",
      "https://science.sciencemag.org/content/early/2020/06/15/science.abd0827\n",
      "https://www.biorxiv.org/content/10.1101/2020.11.06.370676v1\n",
      "https://www.nature.com/articles/s41586-020-2349-y\n",
      "https://science.sciencemag.org/content/early/2020/09/23/science.abe3354\n",
      "https://science.sciencemag.org/content/early/2021/06/30/science.abi7994\n",
      "https://doi.org/10.1016/j.cell.2021.03.028\n",
      "https://www.nature.com/articles/s41586-021-03807-6\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.07.438818v1\n",
      "https://www.nature.com/articles/s41586-021-03817-4\n",
      "https://www.sciencedirect.com/science/article/pii/S0006291X05002263\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.26.441501v1\n",
      "https://www.biorxiv.org/content/10.1101/2020.04.16.045419v2\n",
      "https://www.biorxiv.org/content/10.1101/2020.04.16.045419v2;https://www.biorxiv.org/content/10.1101/2020.11.10.376822v1\n",
      "https://www.nature.com/articles/s41467-020-19204-y\n",
      "https://www.nature.com/articles/s41467-020-18387-8\n",
      "https://www.biorxiv.org/content/10.1101/2021.06.02.446813v1\n",
      "https://www.nature.com/articles/s41467-021-21609-2\n",
      "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009165\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.16.440101v1\n",
      "https://www.nature.com/articles/s41586-021-03738-2\n",
      "https://www.nature.com/articles/s41467-020-18174-5\n",
      "https://www.biorxiv.org/content/10.1101/2020.08.08.242511v1.full.pdf\n",
      "https://advances.sciencemag.org/content/4/8/eaas9667\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867420304943\n",
      "https://science.sciencemag.org/content/early/2021/01/11/science.abe6230\n",
      "https://www.biorxiv.org/content/10.1101/2020.06.09.137935v1\n",
      "https://stm.sciencemag.org/content/13/577/eabf1555\n",
      "https://www.pnas.org/content/118/19/e2101918118\n",
      "https://www.biorxiv.org/content/10.1101/2021.02.08.429275v1\n",
      "https://doi.org/10.1021/acssynbio.0c00566\n",
      "https://www.sciencedirect.com/science/article/pii/S2211124721000127\n",
      "https://www.nature.com/articles/s41586-021-03676-z\n",
      "https://www.sciencedirect.com/science/article/pii/S2211124721004435\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "from paperscraper.pubmed import get_and_dump_pubmed_papers\n",
    "import json\n",
    "from collections import Counter\n",
    "import matplotlib.pyplot as plt\n",
    "def extract_url_without_patents(source):\n",
    "    urls = []\n",
    "    for _ in source:\n",
    "        if len(_.split(\"(h\")) > 1:\n",
    "            url = _.split(\"(\")[1]\n",
    "            url = url.split(\")\")[0]\n",
    "            if url not in urls and len(url) != 0 and 'patent' not in url:\n",
    "                urls.append(url)\n",
    "    return urls\n",
    "df = pd.read_csv (r'/home/sabsr3/Downloads/covabdab.csv')\n",
    "list_of_urls = extract_url_without_patents(df[\"Sources\"])\n",
    "with open(\"url.txt\", \"w\") as f:\n",
    "        for name in list_of_urls:\n",
    "            f.write(str(name) + \"\\n\")\n",
    "            "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "f50ed7ba",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<title>A dominant antigenic epitope on SARS-CoV spike protein identified by an avian single-chain variable fragment (scFv)-expressing phage - ScienceDirect</title>\n"
     ]
    }
   ],
   "source": [
    "from urllib import request\n",
    "from bs4 import BeautifulSoup\n",
    "\n",
    "headers = {'User-Agent': 'Mozilla/5.0 (Windows NT 6.1; WOW64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/56.0.2924.76 Safari/537.36'}\n",
    "page = requests.get(\"https://www.sciencedirect.com/science/article/pii/S0165242707000487\", headers = headers)\n",
    "soup = BeautifulSoup(page.content, 'html.parser')\n",
    "print(soup.title)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "3109cbd7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://science.sciencemag.org/content/early/2020/06/19/science.abc6952/tab-pdf\n",
      "https://www.jimmunol.org/content/early/2020/06/23/jimmunol.2000583\n",
      "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1000197\n",
      "https://www.nature.com/articles/s41421-021-00292-z\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1\n",
      "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1002859\n",
      "https://www.sciencedirect.com/science/article/pii/S0042682206006854\n",
      "https://www.pnas.org/content/pnas/111/19/E2018.full\n",
      "https://academic.oup.com/jid/article/193/5/685/877553\n",
      "https://www.nature.com/articles/s41421-021-00295-w\n",
      "https://www.biorxiv.org/content/10.1101/2020.06.30.178897v1\n",
      "https://www.rcsb.org/structure/7dd2\n",
      "https://www.nature.com/articles/s41423-020-0426-7\n",
      "https://www.nature.com/articles/s41467-020-16256-y\n",
      "https://www.sciencedirect.com/science/article/pii/S2211124720308998\n",
      "https://www.sciencedirect.com/science/article/pii/S2666379121001567\n",
      "https://www.nature.com/articles/cr2015113\n",
      "https://www.sciencedirect.com/science/article/pii/S0165242707000487\n",
      "https://www.biorxiv.org/content/10.1101/2021.05.16.444004v1\n",
      "https://www.biorxiv.org/content/10.1101/2020.11.24.395079v1\n",
      "https://www.rcsb.org/structure/7EAN\n",
      "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0232757;WO2019039891 \n",
      "https://www.rcsb.org/structure/7CR5\n",
      "https://www.nature.com/articles/s41467-019-10897-4\n",
      "https://www.rcsb.org/structure/7EAM\n",
      "https://www.jbc.org/content/281/45/34610.long\n",
      "https://www.biorxiv.org/content/10.1101/2020.12.31.424987v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.02.25.432969v1\n",
      "https://science.sciencemag.org/content/early/2021/06/30/science.abh1766\n",
      "https://www.biorxiv.org/content/10.1101/2021.02.02.429458v1\n",
      "https://www.pnas.org/content/117/47/29832\n",
      "https://academic.oup.com/jid/article/218/8/1249/5017222\n",
      "https://www.biorxiv.org/content/10.1101/2020.08.19.253369v2.full\n",
      "https://www.biorxiv.org/content/10.1101/2021.01.07.425806v1\n",
      "https://cvi.asm.org/content/13/5/594.long\n",
      "https://www.cell.com/cell/fulltext/S0092-8674\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867421002245\n",
      "https://www.sciencedirect.com/science/article/pii/S0006291X05010892\n",
      "https://www.biorxiv.org/content/10.1101/2021.07.05.451203v1\n",
      "https://science.sciencemag.org/content/early/2020/05/12/science.abc2241\n",
      "https://www.nature.com/articles/s41594-021-00596-4\n",
      "https://www.who.int/medicines/publications/druginformation/innlists/PL124-COVID\n",
      "https://www.biorxiv.org/content/10.1101/2020.07.09.195263v1\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867420306206\n",
      "https://www.nature.com/articles/s41422-021-00555-0\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867421005353\n",
      "https://www.sciencedirect.com/science/article/pii/S2589004221004478\n",
      "https://www.nature.com/articles/s41586-020-2456-9\n",
      "https://www.nature.com/articles/s41586-021-03207-w\n",
      "https://www.nature.com/articles/s41586-021-03696-9\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867421008849\n",
      "https://www.biorxiv.org/content/10.1101/2020.05.13.092619v2\n",
      "https://www.biorxiv.org/content/10.1101/2020.11.13.381533v1\n",
      "https://www.nature.com/articles/s41586-021-03324-6\n",
      "https://www.nature.com/articles/s41586-020-2381-y_reference\n",
      "https://www.nature.com/articles/s42003-021-02029-w\n",
      "https://www.nature.com/articles/s41467-021-23074-3#Sec18\n",
      "https://science.sciencemag.org/content/early/2020/06/15/science.abc7520\n",
      "https://jvi.asm.org/content/92/10/e02002-17\n",
      "https://science.sciencemag.org/content/early/2021/05/03/science.abg5268\n",
      "https://doi.org/10.1016/j.cell.2020.06.044\n",
      "https://www.biorxiv.org/content/10.1101/2021.01.26.428356v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.05.02.442326v1\n",
      "https://www.nature.com/articles/s41591-020-0998-x\n",
      "https://science.sciencemag.org/content/early/2020/06/15/science.abc5902\n",
      "https://www.sciencedirect.com/science/article/pii/S009286742100221X\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867421004281\n",
      "https://jvi.asm.org/content/79/3/1635\n",
      "https://www.tandfonline.com/doi/full/10.1080/19420862.2021.1922134\n",
      "https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0030237\n",
      "https://www.biorxiv.org/content/10.1101/2021.09.30.462420v1.full\n",
      "https://www.biorxiv.org/content/10.1101/2020.08.15.252320v1.full\n",
      "https://www.biorxiv.org/content/10.1101/2020.05.12.091298v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.03.23.436684v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.01.437942v1\n",
      "https://www.nature.com/articles/ncomms8712\n",
      "https://www.biorxiv.org/content/10.1101/2021.05.31.446421v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.03.02.433360v1\n",
      "https://www.biorxiv.org/content/10.1101/2020.12.31.424729v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.07.20.453054v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.05.29.443900v1\n",
      "https://www.biorxiv.org/content/10.1101/2021.02.12.430940v1\n",
      "https://www.biorxiv.org/content/10.1101/2020.06.12.148387v1\n",
      "https://www.sciencedirect.com/science/article/pii/S0161589004002548\n",
      "https://www.sciencedirect.com/science/article/pii/S0022283609003374\n",
      "https://www.nature.com/articles/s41467-021-23825-2\n",
      "https://www.sciencedirect.com/science/article/pii/S1931312821001335\n",
      "https://www.nature.com/articles/s41586-020-2571-7\n",
      "https://www.rcsb.org/structure/7KXK\n",
      "https://www.nature.com/articles/s41422-020-00446-w\n",
      "https://www.cell.com/cell-reports/fulltext/S2211-1247\n",
      "https://www.pnas.org/content/114/35/E7348\n",
      "https://onlinelibrary.wiley.com/doi/10.1002/mco2.60\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.07.438849v2\n",
      "https://www.biorxiv.org/content/10.1101/2020.06.02.129098v2\n",
      "https://www.nature.com/articles/s41594-020-0469-6\n",
      "https://www.semanticscholar.org/paper/A-human-neutralizing-antibody-against-a-epitope-by-Duan-Ji/ca990dfe192853fc9fc107398352b16a5c45d39b/figure/2\n",
      "https://academic.oup.com/nsr/article/8/3/nwaa297/6041739\n",
      "https://www.science.org/doi/full/10.1126/scitranslmed.abi7826\n",
      "https://www.researchsquare.com/article/rs-548968/v1\n",
      "https://www.jbc.org/content/295/36/12814.full\n",
      "https://www.biorxiv.org/content/10.1101/2020.12.29.424711v1\n",
      "https://www.sciencedirect.com/science/article/pii/S2451945621002646\n",
      "https://www.sciencedirect.com/science/article/pii/S0006291X05023417\n",
      "https://www.pnas.org/content/pnas/112/33/10473.full\n",
      "https://www.biorxiv.org/content/10.1101/2020.06.09.143438v1\n",
      "https://www.sciencedirect.com/science/article/pii/S0166093407002236\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.30.442182v3\n",
      "https://www.biorxiv.org/content/10.1101/2020.09.30.318972v1\n",
      "https://cvi.asm.org/content/13/8/953\n",
      "https://www.nature.com/articles/ncomms9223\n",
      "https://jvi.asm.org/content/88/14/7796\n",
      "https://www.sciencedirect.com/science/article/pii/S0006291X11022984\n",
      "https://www.jbc.org/content/281/23/15829.long\n",
      "https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.79\n",
      "https://science.sciencemag.org/content/early/2020/06/15/science.abc7424\n",
      "https://www.nature.com/articles/s41598-021-88809-0\n",
      "https://www.biorxiv.org/content/10.1101/2020.09.03.280370v1.full\n",
      "https://academic.oup.com/jid/article/215/12/1807/3786458\n",
      "https://www.nature.com/articles/s41467-020-18159-4\n",
      "https://stm.sciencemag.org/content/6/234/234ra59.long\n",
      "https://www.biorxiv.org/content/10.1101/2021.06.04.447066v1\n",
      "https://www.rcsb.org/structure/7DPM\n",
      "https://www.biorxiv.org/content/10.1101/2021.09.14.460356v1\n",
      "https://www.sciencedirect.com/science/article/pii/S1286457907001724\n",
      "https://elifesciences.org/articles/64815\n",
      "https://science.sciencemag.org/content/early/2020/11/04/science.abe3255\n",
      "https://science.sciencemag.org/content/early/2020/11/04/science.abe4747\n",
      "https://www.biorxiv.org/content/10.1101/2020.08.09.242867v1.full\n",
      "https://www.biorxiv.org/content/10.1101/2020.12.09.417741v1\n",
      "https://www.nature.com/articles/s41467-021-25153-x#Sec34\n",
      "https://www.nature.com/articles/s41598-020-79036-0\n",
      "https://www.embopress.org/doi/full/10.15252/embr.202052325\n",
      "https://pubs.acs.org/doi/10.1021/acs.analchem.1c00677\n",
      "https://www.sciencedirect.com/science/article/pii/S1074761321001357\n",
      "https://advances.sciencemag.org/content/early/2021/04/22/sciadv.abg7607\n",
      "https://www.nature.com/articles/s41422-020-00444-y\n",
      "https://www.nature.com/articles/s41467-021-24514-w\n",
      "https://www.biorxiv.org/content/10.1101/2020.10.13.336800v1\n",
      "https://www.nature.com/articles/s41586-020-2380-z\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://www.rcsb.org/structure/7CJI\n",
      "http://www.rcsb.org/structure/7CDI\n",
      "https://science.sciencemag.org/content/early/2021/08/03/science.abj3321\n",
      "https://www.nature.com/articles/s41467-021-22926-2\n",
      "https://www.sciencedirect.com/science/article/pii/S2211124721012869\n",
      "https://www.biorxiv.org/content/10.1101/2021.01.03.425141v1\n",
      "https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3001209\n",
      "https://www.biorxiv.org/content/10.1101/2021.07.08.451649v1\n",
      "https://www.jbc.org/article/S0021-9258\n",
      "https://www.nature.com/articles/s41594-021-00652-z\n",
      "https://www.researchsquare.com/article/rs-105739/v1\n",
      "https://www.biorxiv.org/content/10.1101/2020.11.11.378778v1\n",
      "https://www.embopress.org/doi/full/10.15252/embj.2021107985\n",
      "https://www.pnas.org/content/112/28/8738\n",
      "https://science.sciencemag.org/content/early/2020/06/15/science.abd0827\n",
      "https://www.biorxiv.org/content/10.1101/2020.11.06.370676v1\n",
      "https://www.nature.com/articles/s41586-020-2349-y\n",
      "https://science.sciencemag.org/content/early/2020/09/23/science.abe3354\n",
      "https://science.sciencemag.org/content/early/2021/06/30/science.abi7994\n",
      "https://doi.org/10.1016/j.cell.2021.03.028\n",
      "https://www.nature.com/articles/s41586-021-03807-6\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.07.438818v1\n",
      "https://www.nature.com/articles/s41586-021-03817-4\n",
      "https://www.sciencedirect.com/science/article/pii/S0006291X05002263\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.26.441501v1\n",
      "https://www.biorxiv.org/content/10.1101/2020.04.16.045419v2\n",
      "https://www.biorxiv.org/content/10.1101/2020.04.16.045419v2;https://www.biorxiv.org/content/10.1101/2020.11.10.376822v1\n",
      "https://www.nature.com/articles/s41467-020-19204-y\n",
      "https://www.nature.com/articles/s41467-020-18387-8\n",
      "https://www.biorxiv.org/content/10.1101/2021.06.02.446813v1\n",
      "https://www.nature.com/articles/s41467-021-21609-2\n",
      "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009165\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.16.440101v1\n",
      "https://www.nature.com/articles/s41586-021-03738-2\n",
      "https://www.nature.com/articles/s41467-020-18174-5\n",
      "https://www.biorxiv.org/content/10.1101/2020.08.08.242511v1.full\n",
      "https://advances.sciencemag.org/content/4/8/eaas9667\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867420304943\n",
      "https://science.sciencemag.org/content/early/2021/01/11/science.abe6230\n",
      "https://www.biorxiv.org/content/10.1101/2020.06.09.137935v1\n",
      "https://stm.sciencemag.org/content/13/577/eabf1555\n",
      "https://www.pnas.org/content/118/19/e2101918118\n",
      "https://www.biorxiv.org/content/10.1101/2021.02.08.429275v1\n",
      "https://doi.org/10.1021/acssynbio.0c00566\n",
      "https://www.sciencedirect.com/science/article/pii/S2211124721000127\n",
      "https://www.nature.com/articles/s41586-021-03676-z\n",
      "https://www.sciencedirect.com/science/article/pii/S2211124721004435\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "from urllib import request\n",
    "from bs4 import BeautifulSoup\n",
    "from paperscraper.pubmed import get_and_dump_pubmed_papers\n",
    "\n",
    "def extract_url_without_patents(source):\n",
    "    urls = []\n",
    "    for _ in source:\n",
    "        if len(_.split(\"(h\")) > 1:\n",
    "            url = _.split(\"(\")[1]\n",
    "            url = url.split(\")\")[0]\n",
    "            url = url.split('.pdf')[0]\n",
    "            if url not in urls and len(url) != 0 and 'patent' not in url and url != 'https://www.cell.com/action/showPdf?pii=S1074-7613%2821%2900359-9':\n",
    "                urls.append(url)\n",
    "    return urls\n",
    "\n",
    "def get_title_from_url(list):\n",
    "    results = []\n",
    "    for _ in list:\n",
    "        print(_)\n",
    "        headers = {'User-Agent': 'Mozilla/5.0 (X11; Ubuntu; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/55.0.2919.83 Safari/537.36'}\n",
    "        r = requests.get(_ , headers=headers)\n",
    "        soup = BeautifulSoup(r.content, 'html.parser')\n",
    "        if soup.title != None:\n",
    "            results.append(soup.title.string)\n",
    "    return results\n",
    "\n",
    "df = pd.read_csv (r'/home/sabsr3/Downloads/covabdab.csv')\n",
    "list_of_urls = extract_url_without_patents(df[\"Sources\"])\n",
    "titles = get_title_from_url(list_of_urls)\n",
    "with open(\"titles.txt\", \"w\") as f:\n",
    "        for name in titles:\n",
    "            f.write(str(name) + \"\\n\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "60c9db1a",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('titles.txt') as f:\n",
    "    titles = f.read().splitlines()\n",
    "    \n",
    "title = []\n",
    "for t in titles:\n",
    "    t = t.split(\" - S\")[0]\n",
    "    t = t.split(\" | \")[0]\n",
    "    title.append(t)\n",
    "with open(\"titles_edited.txt\", \"w\") as f:\n",
    "        for name in title:\n",
    "            f.write(str(name) + \"\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "cd579563",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2', 'A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection', 'Broadening of Neutralization Activity to Directly Block a Dominant Antibody-Driven SARS-Coronavirus Evolution Pathway', 'Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants', 'Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants', 'Structural Bases of Coronavirus Attachment to Host Aminopeptidase N and Its Inhibition by Neutralizing Antibodies', 'Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse®', 'Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution', 'Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters', 'Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries', 'A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies', 'RCSB PDB - 7DD2: S-3C1-F2 structure, two RBDs are up and one RBD is down, the two up RBD bind with a 3C1 fab.', 'Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor', 'A human monoclonal antibody blocking SARS-CoV-2 infection', 'Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection', 'Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions', 'A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein', 'A dominant antigenic epitope on SARS-CoV spike protein identified by an avian single-chain variable fragment (scFv)-expressing phage', 'Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition', 'A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro', 'RCSB PDB - 7EAN: immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 6D6', 'RCSB PDB - 7CR5: Complex structure of a human monoclonal antibody with SARS-CoV-2 nucleocapsid protein NTD', 'Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein', 'RCSB PDB - 7EAM: immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 7D6', 'Structural Basis of Neutralization by a Human Anti-severe Acute Respiratory Syndrome Spike Protein Antibody, 80R* - Journal of Biological Chemistry', 'Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses', 'Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants', 'Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants', 'Naive human B cells can neutralize SARS-CoV-2 through recognition of its receptor binding domain', 'Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection', 'Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient', 'A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD', 'Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library', 'Production of an Anti-Severe Acute Respiratory Syndrome (SARS) Coronavirus Human Monoclonal Antibody Fab Fragment by Using a Combinatorial Immunoglobulin Gene Library Derived from Patients Who Recovered from SARS', 'Extremely potent human monoclonal antibodies from COVID-19 convalescent patients', 'A human SARS-CoV neutralizing antibody against epitope on S2 protein', 'Mouse Antibodies with Activity Against the SARS-CoV-2 D614G and B.1.351 Variants', 'A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2', 'Structural basis for broad coronavirus neutralization', 'Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency', 'Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells', 'Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants', 'B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV', 'Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice', 'Convergent antibody responses to SARS-CoV-2 in convalescent individuals', 'Evolution of antibody immunity to SARS-CoV-2', 'Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection', 'Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike', 'Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals', 'Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2', 'mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants', 'Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2', 'Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection', 'Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model', 'Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape', 'Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes', 'Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain', 'Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals', 'Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein', 'Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability', 'The antigenic anatomy of SARS-CoV-2 receptor binding domain', 'Antibody evasion by the P.1 strain of SARS-CoV-2', 'Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus', 'Full article: Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies', 'Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants', 'SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies', 'A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model', 'Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual', 'Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects', 'Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants', 'Evaluation of candidate vaccine approaches for MERS-CoV', 'Accelerated Antibody Discovery Targeting the SARS-CoV-2 Spike Protein for COVID-19 Therapeutic Potential', 'Fragment-based computational design of antibodies targeting structured epitopes', 'The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates', 'Discovery of nanobodies against SARS-CoV-2 and an uncommon neutralizing mechanism', 'Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution', 'Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2', 'Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient', 'Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus', 'Structural Insights into Immune Recognition of the Severe Acute Respiratory Syndrome Coronavirus S Protein Receptor Binding Domain', 'Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers', 'Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite', 'Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike', 'RCSB PDB - 7KXK: SARS-CoV-2 spike protein in complex with Fab 15033-7, 2-\"up\"-1-\"down\" conformation', 'Structure-based development of human antibody cocktails against SARS-CoV-2', 'Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen', 'A potent neutralizing nanobody against SARS‐CoV‐2 with inhaled delivery potential - Gai - 2021 - MedComm - Wiley Online Library', 'Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality', 'Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody', 'Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2', 'Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2', 'An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models', 'A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19', 'Identification of an anti–SARS–CoV-2 receptor-binding domain–directed human monoclonal antibody from a naïve semisynthetic library - Journal of Biological Chemistry', 'Deep mining of early antibody response in COVID-19 patients yields potent neutralisers and reveals high level of convergence', 'Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis', 'Cross-reactivity of antibody against SARS-coronavirus nucleocapsid protein with IL-11', 'Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus', 'Potent synthetic nanobodies against SARS-CoV-2 and molecular basis for neutralization', 'Chicken single-chain variable fragments against the SARS-CoV spike protein', 'LY-CoV1404 potently neutralizes SARS-CoV-2 variants', 'LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection', 'Human Neutralizing Fab Molecules against Severe Acute Respiratory Syndrome Coronavirus Generated by Phage Display', 'Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody', 'Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies', 'Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens', 'Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody* - Journal of Biological Chemistry', 'Potent neutralizing RBD‐specific antibody cocktail against SARS‐CoV‐2 and its mutant - Jia - 2021 - MedComm - Wiley Online Library', 'Broad neutralization of SARS-related viruses by human monoclonal antibodies', 'Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies', 'Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies', 'Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset', 'A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes', 'Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein', 'Human single-chain antibodies neutralize SARS-CoV-2 variants by engaging an essential epitope of the spike: a new weapon against COVID-19', 'RCSB PDB - 7DPM: Crystal structure of SARS-CoV-2 Spike RBD in complex with MW06 Fab', 'Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display', 'Isolation and identification of an scFv antibody against nucleocapsid protein of SARS-CoV', 'The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates', 'An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike', 'Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2', 'A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential', 'Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies', 'Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics', 'High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme', 'NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies', 'Single-Domain Antibodies for the Detection of SARS-CoV-2 Nucleocapsid Protein', 'Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant', 'SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity', 'Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection', 'Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2', 'Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies', 'Human neutralizing antibodies elicited by SARS-CoV-2 infection', 'RCSB PDB - 7CJI: Photosystem II structure in the S1 state', 'RCSB PDB - 7CDI: Crystal structure of SARS-CoV-2 antibody P2C-1F11 with RBD', 'Broad betacoronavirus neutralization by a stem helix–specific human antibody', 'A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes', 'Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain', 'Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry', 'Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes', 'Structure of a germline-like human antibody defines a neutralizing epitope on the SARS-CoV-2 spike NTD', 'Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function', 'Development of Multivalent Nanobodies Blocking SARS CoV 2 Infection by Targeting RBD of Spike Protein', 'Rapid generation of potent antibodies by autonomous hypermutation in yeast', 'Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies', 'Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection', 'Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail', 'Potent SARS-CoV-2 neutralizing antibodies selected from a human antibody library constructed decades ago', 'Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody', 'Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms', 'SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern', 'SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape', 'Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody', 'Broad sarbecovirus neutralization by a human monoclonal antibody', 'Identification of single-chain antibody fragments specific against SARS-associated coronavirus from phage-displayed antibody library', 'A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope', 'Sybodies targeting the SARS-CoV-2 receptor-binding domain', 'Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2', 'Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain', 'Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking', 'SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface', 'Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors', 'A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model', 'SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses', 'An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction', 'Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike', 'Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection', 'Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies', 'Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape', 'Fast isolation of sub-nanomolar affinity alpaca nanobody against the Spike RBD of SARS-CoV-2 by combining bacterial display and a simple single-step density gradient selection', 'Enhanced SARS-CoV-2 neutralization by dimeric IgA', 'Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice', 'A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration', 'Toolkit for Quickly Generating and Characterizing Molecular Probes Specific for SARS-CoV-2 Nucleocapsid as a Primer for Future Coronavirus Pandemic Preparedness', 'Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD', 'Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants', 'Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2']\n",
      "['12-month SARS-CoV-2 antibody persistency in a\\xa0Tyrolean COVID-19 cohort.', 'Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving Tumor Necrosis Factor-α inhibitors.', 'Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.', 'Functional Antibodies Against SARS-CoV-2 Receptor Binding Domain Variants with Mutations N501Y or E484K in Human Milk from COVID-19-Vaccinated, -Recovered, and -Unvaccinated Women.', 'Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial.', 'Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus.', 'Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2.', 'Discordance Between SARS-CoV-2-specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients.', 'Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection.', 'Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape.', 'An Intranasal Vaccine Based on Outer Membrane Vesicles Against SARS-CoV-2.', 'An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms.', 'Descriptive Evaluation of Antibody Responses to SARS-CoV-2 Infection in Plasma and Gingival Crevicular Fluid in a Nursing Home Cohort-Arkansas, June-August 2020.', 'Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients.', 'Current and future nanoparticle vaccines for COVID-19.', 'Design of a population-based longitudinal cohort study of SARS-CoV-2 incidence and prevalence among adults in the San Francisco Bay Area.', 'Contributions of single-particle cryoelectron microscopy toward fighting COVID-19.', 'Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4', 'Mechanistic principles of an ultra-long bovine CDR reveal strategies for antibody design.', 'Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant.', 'Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine.', 'COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals.', 'SARS-CoV-2 Antibody Response is Associated with Age in Convalescent Outpatients.', 'SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity.', 'Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern.', 'Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia.', 'A case with SARS-CoV-2 reinfection from India.', 'Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability.', 'Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.', 'Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.', 'A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.', 'Landscapes and dynamic diversifications of B-cell receptor repertoires in COVID-19 patients.', 'Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection.', 'Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2.', 'Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.', 'Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2.', \"Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups.\", 'Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage.', 'Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy.', 'Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.', 'Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice.', 'Divergent COVID-19 Disease Trajectories Predicted by a DAMP-Centered Immune Network Model.', 'Site-Specific and Stable Conjugation of the SARS-CoV-2 Receptor-Binding Domain to Liposomes in the Absence of Any Other Adjuvants Elicits Potent Neutralizing Antibodies in BALB/c Mice.', 'Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice.', 'Computational redesign of Fab CC12.3 with substantially better predicted binding affinity to SARS-CoV-2 than human ACE2 receptor.', \"A Review of Human Coronaviruses' Receptors: The Host-Cell Targets for the Crown Bearing Viruses.\", 'Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study.', 'Modeling Coronavirus Spike Protein Dynamics: Implications for Immunogenicity and Immune Escape.', 'Immunogenicity and Adverse Effect of Two Dose BNT162b2 mRNA Vaccine Among Liver Transplant Recipients.', 'Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19.', 'Interaction Analysis on the SARS-CoV-2 Spike Protein Receptor Binding Domain Using Visualization of the Interfacial Electrostatic Complementarity.', 'Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA.', 'Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency.', 'Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies.', 'The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials.', 'A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2.', 'Elucidating important structural features for the binding affinity of spike - SARS-CoV-2 neutralizing antibody complexes.', 'RBD', 'Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein.', 'Oral vaccination protects against SARS-CoV-2 in a Syrian hamster challenge model.', 'High Induction of IL-6 Secretion From hUCMSCs Optimize the Potential of hUCMSCs and TCZ as Therapy for COVID-19-Related ARDS.', 'Association of Human Milk Antibody Induction, Persistence, and Neutralizing Capacity With SARS-CoV-2 Infection vs mRNA Vaccination.', 'Post-acute COVID-19 syndrome after reinfection and vaccine breakthrough by the SARS-CoV-2 Gamma variant in Brazil.', 'Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate.', 'High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.', 'SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays.', 'Mutation profile of SARS-CoV-2 spike protein and identification of potential multiple epitopes within spike protein for vaccine development against SARS-CoV-2.', 'Sandwich/competitive immuno-sensors on micro-interface for SARS-CoV-2 neutralizing antibodies.', 'COVID-19 Associated Coagulopathy: Mechanisms and Host-Directed Treatment.', '\"Polymutant\" Spike Points Way Toward More Durable COVID-19 Vaccine.', 'Camel nanobodies broadly neutralize SARS-CoV-2 variants.', 'mRNA Vaccines Induce Rapid Antibody Responses in Mice.', 'Prevalence of SARS-CoV-2 Antibody in 2,935 Healthcare Workers at 6 Major Hospitals, Daegu, Korea.', 'Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant.', 'Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.', 'Susceptibility of livestock to SARS-CoV-2 infection.', 'SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response.', 'Transmission dynamics, clinical characteristics and sero-surveillance in the COVID-19 outbreak in a population dense area of Colombo, Sri Lanka April- May 2020.', 'An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine \"Sputnik Light\" for prevention of coronavirus infection in healthy adults.', 'Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection.', 'Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern.', 'The majority of SARS-CoV-2-specific antibodies in COVID-19 patients with obesity are autoimmune and not neutralizing.', 'Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations.', 'Timing of SARS-CoV-2 vaccination during the third trimester of pregnancy and transplacental antibody transfer: a prospective cohort study.', 'First cases of SARS-CoV-2 infection in dogs and cats in Thailand.', 'Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern.', 'Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants.', 'Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNe-short- And long-term Immune reSponSe evAluatioN in health Care workErs.', 'Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models.', 'Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.', 'Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants.', 'Generation and Effect Testing of a SARS-CoV-2 RBD-Targeted Polyclonal Therapeutic Antibody Based on a 2-D Airway Organoid Screening System.', 'A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants.', 'Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine.', 'SARS-CoV-2 infection long time after full vaccination is related to a lack of neutralizing antibodies.', 'T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination.', 'Limited impact of Delta variantâ€™s mutations in the effectiveness of neutralization conferred by natural infection or COVID-19 vaccines in a Latino population.', 'The humanized nanobody RBD-1-2G tolerates the spike N501Y mutation to neutralize SARS-CoV-2.', 'Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway.', 'Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran.', 'Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants.', 'Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.', 'A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters.', 'Large-scale study on virological and serological prevalence of SARS-CoV-2 in cats and dogs in Spain.', 'Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models.', 'A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates.', \"Polyclonal F(ab')\", 'Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient.', 'Casirivimab/Imdevimab: First Approval.', 'Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago.', 'Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.', 'The evaluation of novel oral vaccines based on self-amplifying RNA lipid nanparticles (saRNA LNPs), saRNA transfected Lactobacillus plantarum LNPs, and saRNA transfected Lactobacillus plantarum to neutralize SARS-CoV-2 variants alpha and delta.', 'Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an inactivated COVID-19 vaccine.', 'Elevated cytokines and chemokines in peripheral blood of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.', 'The Current Status of COVID-19 Vaccines.', 'Kinetics of Neutralizing Antibody Response Underscores Clinical COVID-19 Progression.', 'The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.', 'Scientific rationale for developing potent RBD-based vaccines targeting COVID-19.', 'A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge.', 'Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men.', 'Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.', 'Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation.', 'Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain.', 'Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.', 'Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker.', 'Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery Against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques.', 'Gold-Nanostar-Chitosan-Mediated Delivery of SARS-CoV-2 DNA Vaccine for Respiratory Mucosal Immunization: Development and Proof-of-Principle.', \"Monoclonal Antibodies for COVID-19 Preexposure Prophylaxis Can't Come Fast Enough for Some People.\", 'An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.', 'Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies.', 'Detection of SARS-CoV-2 in two cats during the second wave of the COVID-19 pandemic in France.', 'Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts.', 'Impaired Neutralizing Antibody Response to COVID-19 mRNA Vaccines in Cancer Patients.', 'Increased in vitro neutralizing activity of SARS-CoV-2 IgA1 dimers compared to monomers and IgG.', 'Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child.', 'Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid.', 'Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice.', 'Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines.', 'How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika.', 'Viral Shedding among Re-Positive Severe Acute Respiratory Syndrome Coronavirus-2 Positive Individuals in Republic of Korea.', 'SARS-CoV-2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro.', 'Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme-The South African Experience.', 'Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients.', 'An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants.', 'Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.', \"Xeno-Nucleic Acid (XNA) 2'-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor-Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding.\", 'Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination.', 'Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2.', 'Monoclonal Antibodies to S and N SARS-CoV-2 Proteins as Probes to Assess Structural and Antigenic Properties of Coronaviruses.', 'Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil.', 'BNT162b2 mRNA Vaccination Leads to Long-Term Protection from COVID-19 Disease.', 'Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors.', 'Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination.', 'Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient.', 'SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration.', 'Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks.', 'Weak Cross-Lineage Neutralization by Anti SARS-CoV-2 Spike Antibodies after Natural Infection or Vaccination Is Rescued by Repeated Immunological Stimulation.', 'A Single Dose of a Hybrid hAdV5-Based Anti-COVID-19 Vaccine Induces a Long-Lasting Immune Response and Broad Coverage against VOC.', 'Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers.', 'Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers.', 'Bifunctional molecules targeting SARS-CoV-2 spike and the polymeric Ig receptor display neutralization activity and mucosal enrichment.', 'BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study.', 'Serum IgG anti-SARS-CoV-2 Binding Antibody Level Is Strongly Associated With IgA and Functional Antibody Levels in Adults Infected With SARS-CoV-2.', 'Correlation between ABO blood group and neutralizing anti-SARS-CoV-2 antibody titers in convalescent plasma donations.', 'Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients.', 'Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: A double-blind, randomized controlled phase 1/2 trial.', 'Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate.', 'Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner.', 'Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients.', 'Single-dose replicating poxvirus vector-basedRBD vaccine drives robust humoral and T\\xa0cellimmune response against SARS-CoV-2 infection.', 'Persistence at one year of neutralizing antibodies after SARS-CoV-2 infection: Influence of initial severity and steroid use.', 'A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti-SARS-CoV-2 Monoclonal antibodies to Advance Bamlanivimab into a First-in-Human Clinical Trial.', 'BCEPS: A Web Server to Predict Linear B Cell Epitopes with Enhanced Immunogenicity and Cross-Reactivity.', 'Highly Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA.', 'Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals.', 'Persistence of Antibody Responses to the SARS-CoV-2 in Dialysis Patients and Renal Transplant Recipients Recovered from COVID-19.', 'Severity, Pathogenicity and Transmissibility of Delta and Lambda Variants of SARS-CoV-2, Toxicity of Spike Protein and Possibilities for Future Prevention of COVID-19.', 'Impact of Host Immune Status on Discordant Anti-SARS-CoV-2 Circulating B Cell Frequencies and Antibody Levels.', 'Immune Responses against SARS-CoV-2-Questions and Experiences.', 'Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests-A Population-Based Evaluation.', 'Recombinant Protein Expression and Purification of N, S1, and RBD of SARS-CoV-2 from Mammalian Cells and Their Potential Applications.', 'Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples.', 'A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.', 'COVID-19 reinfection in the presence of neutralizing antibodies.', 'Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2.', 'Antibodies from previous infection bring sufficient and long-term protection against COVID-19.', 'Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be?', 'Structure-guided antibody cocktail for prevention and treatment of COVID-19.', 'Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination.', 'Cowpea Mosaic Virus Nanoparticle Vaccine Candidates Displaying Peptide Epitopes Can Neutralize the Severe Acute Respiratory Syndrome Coronavirus.', 'DNA-Directed Patterning for Versatile Validation and Characterization of a Lipid-Based Nanoparticle Model of SARS-CoV-2.', 'Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody.', 'A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant Recipients.', 'Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report.', 'Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.', 'A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses.', 'A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy.', 'Quantum Optical Immunoassay: Upconversion Nanoparticle-based Neutralizing Assay for COVID-19.', 'Symptoms, SARS-CoV-2 Antibodies, and Neutralization Capacity in a Cross Sectional-Population of German Children.', 'Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies.', 'Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.', 'Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening.', 'An alphavirus replicon-based vaccine expressing a stabilized Spike antigen induces protective immunity and prevents transmission of SARS-CoV-2 between cats.', 'COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.', 'Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants.', 'Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants.', 'Immune characterization of a Colombian family cluster with SARS-CoV-2 infection.', 'SARS-CoV-2 Antibody Binding and Neutralization in Dried Blood Spot Eluates and Paired Plasma.', 'Generation and persistence of S1\\xa0IgG and neutralizing antibodies in post-COVID-19 patients.', 'Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern.', '[Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].', '[Periodic Evaluation of Anti-SARS-CoV-2 Antibody Levels and Determination of Surrogate Virus Neutralization in Healthcare Workers with COVID-19].', 'Systemic autoimmune myopathies: A prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.', 'Atomistic Simulations and In Silico Mutational Profiling of Protein Stability and Binding in the SARS-CoV-2 Spike Protein Complexes with Nanobodies: Molecular Determinants of Mutational Escape Mechanisms.', 'Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.', 'Mild and Asymptomatic COVID-19 Convalescents Present Long-Term Endotype of Immunosuppression Associated With Neutrophil Subsets Possessing Regulatory Functions.', 'BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents.', 'Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.', 'Asymptomatic and Mild SARS-CoV-2 Infections Elicit Lower Immune Activation and Higher Specific Neutralizing Antibodies in Children Than in Adults.', 'Seroprevalence of SARS-CoV-2 in Croatian solid-organ transplant recipients.', 'COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view.', 'Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: decline in antibodies 12 weeks after two doses.', 'SARS-CoV-2-specific Humoral and Cell-mediated Immune Responses after Immunization with Inactivated COVID-19 Vaccine in Kidney Transplant Recipients (CVIM 1 Study).', 'Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD.', 'Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.', 'A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.', 'The role of COVID-19 survivor status and gender towards neutralizing antibody titers 1, 2, 3 months after Sinovac vaccine administration on clinical-year medical students in Indonesia.', 'SARS COV-2- IgG antibodies in blood donors in pandemic\\xa0-\\xa0A game changer for policy makers.', 'Receptor binding domain-IgG levels correlate with protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks.', 'Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?', 'Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin.', 'One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.', 'Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2.', \"China's COVID vaccines have been crucial - now immunity is waning.\", 'INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants.', 'Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.', 'Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects.', 'The SARS CoV-2 spike directed non-neutralizing polyclonal antibodies cross-react with Human immunodeficiency virus (HIV-1) gp41.', 'A poor and delayed anti-SARS-CoV2 IgG response is associated to severe COVID-19 in children.', 'In\\xa0vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential.', 'Structure-Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda.', 'The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization.', 'Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.', 'Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection.', 'Impact of Specific ', 'Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants.', 'SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.', 'Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters.', 'StatPearls', 'StatPearls', 'A novel linear and broadly neutralizing peptide in the SARS-CoV-2 S2 protein for universal vaccine development.', 'No crossreactivity of anti-SARS-CoV-2 spike protein antibodies with Syncytin-1.', 'Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects.', 'Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.', 'SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection.', 'Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena valley.', 'Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls.', '[Research progress on antibody-dependent enhancement in infectious diseases].', 'A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.', 'ESC: a comprehensive resource for SARS-CoV-2 immune escape variants.', 'Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.', 'Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial.', 'Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals.', '', 'Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies.', 'Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.', 'Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age.', 'Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro.', 'Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance.', 'Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains.', 'Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy.', 'Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.', '[The involvement of vitamin A in the production of secretory IgA in the respiratory epithelium for potential protection against SARS-CoV-2 infection].', 'VarEPS: an evaluation and prewarning system of known and virtual variations of SARS-CoV-2 genomes.', 'Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.', 'Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant.', 'Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment.', 'SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement.', 'Breastfeeding and the developmental origins of mucosal immunity: how human milk shapes the innate and adaptive mucosal immune systems.', '[A functional platform to monitor SARS-CoV-2-specific T cell responses in vaccinated individuals and COVID-19 recovered patients].', 'Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85\\xa0years of age in Greece: the GREVAXIMO study.', 'Discrepancy between frequent occurrence of COVID-19-like symptoms and low seroconversion rates among healthcare workers.', 'Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease.', 'SARS-CoV-2 Lambda (C.37): An emerging variant of concern?', 'PRAK-03202: A triple antigen virus-like particle vaccine candidate against SARS CoV-2.', 'N-terminal domain mutations of the spike protein are structurally implicated in epitope recognition in emerging SARS-CoV-2 strains.', 'α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants.', 'Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody.', 'Peptides Derived From S and N Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 Induce T Cell Responses: A Proof of Concept for T Cell Vaccines.', 'Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients.', 'A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies.', 'Clinical and immunological characteristics in COVID-19 convalescent patients.', 'Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses.', 'Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals.', 'Silent SARS-CoV-2 Infections, Waning Immunity, Serology Testing, and COVID-19 Vaccination: A Perspective.', 'Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen.', 'ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.', 'SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques.', 'A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59\\xa0years: An interim analysis in Indonesia.', 'Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination.', 'Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.', 'Polymersomes as Stable Nanocarriers for a Highly Immunogenic and Durable SARS-CoV-2 Spike Protein Subunit Vaccine.', 'Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU.', 'Spread of Mink SARS-CoV-2 Variants in Humans: A Model of Sarbecovirus Interspecies Evolution.', 'Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA.', 'Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers.', 'mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants.', 'B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination.', 'Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.', 'Comparison of the Results of Five SARS-CoV-2 Antibody Assays before and after the First and Second ChAdOx1 nCoV-19 Vaccinations among Health Care Workers: a Prospective Multicenter Study.', 'Molecular switches regulating the potency and immune evasiveness of SARS-CoV-2 spike protein.', 'SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19.', 'Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.', 'One-year sustained cellular and humoral immunities of COVID-19 convalescents.', 'An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models.', 'An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam.', 'SARS-CoV-2-Reactive Mucosal B Cells in the Upper Respiratory Tract of Uninfected Individuals.', 'A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.', 'Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H.', 'Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests.', 'Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies.', 'Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies.', 'Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model.', 'Immunological Approaches to the Treatment of New Coronavirus Infection (Review).', 'Spike and neutralizing antibodies response to COVID-19 vaccination in haemodialysis patients.', 'Follicular Helper T Cells in the Immunopathogenesis of SARS-CoV-2 Infection.', 'Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge.', 'A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.', 'Long-Term Elevated Inflammatory Protein Levels in Asymptomatic SARS-CoV-2 Infected Individuals.', 'Rapid antibody testing for SARS-CoV-2 vaccine response in pediatric healthcare workers.', 'Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples.', 'A highly potent antibody effective against SARS-CoV-2 variants of concern.', 'The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine.', 'Emergence and spread of SARS-CoV-2 lineage B.1.620 with variant of concern-like mutations and deletions.', 'Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.', 'Neutralizing antibodies directed against SARS-CoV-2 in a population residing in a nursing home and a long-term care unit.', 'Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.', 'Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.', 'SARS-CoV-2 spike protein receptor-binding domain N-glycans facilitate viral internalization in respiratory epithelial cells.', 'Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.', 'Potent neutralization of SARS-CoV-2 including variants of concern by vaccines presenting the receptor-binding domain multivalently from nanoscaffolds.', 'Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.', 'Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study.', 'State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.', 'Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses.', 'Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.', 'mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant.', 'Versatile and rapid microfluidics-assisted antibody discovery.', 'To study heterogeneity in SARS-CoV-2 IgG response titre in patients recovered from COVID-19.', 'SCIGA: Software for large-scale, single-cell immunoglobulin repertoire analysis.', 'Recovery of Memory B-cell Subsets and Persistence of Antibodies in Convalescent COVID-19 Patients.', 'Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study.', 'A Self-Biomineralized Novel Adenovirus Vectored COVID-19 Vaccine for Boosting Immunization of Mice.', 'Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV-2 Spike Glycoprotein.', 'Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans.', 'Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals.', 'Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2.', 'Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.', 'Biomaterials and Oxygen Join Forces to Shape the Immune Response and Boost COVID-19 Vaccines.', 'COVID-19 Repeated Convalescent Plasma Collection: Analysis of 149 Donations from 88 French Military Health Workers.', 'Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants.', 'Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.', 'Neutralization antibody titers against SARS-CoV-2 in an infant born to a mother with COVID-19.', 'Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2.', 'Immunological Analysis of People in Northeast China after SARS-CoV-2 Inactivated Vaccine Injection.', 'Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque.', 'Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines.', 'Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report.', 'A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine.', 'Plant-Expressed Receptor Binding Domain of the SARS-CoV-2 Spike Protein Elicits Humoral Immunity in Mice.', 'COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity.', 'Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.', 'One Health Investigation of SARS-CoV-2 Infection and Seropositivity among Pets in Households with Confirmed Human COVID-19 Cases-Utah and Wisconsin, 2020.', 'SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters.', 'Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q.', 'Monitoring Natural SARS-CoV-2 Infection in Lions (', 'BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects.', 'Discrepancies in Infectivity of Flavivirus and SARS-CoV-2 Clinical Samples: An Improved Assay for Infectious Virus Shedding and Viremia Assessment.', 'Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews.', 'Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group.', 'Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency.', 'Low SARS-CoV-2 Seroprevalence and No Active Infections among Dogs and Cats in Animal Shelters with Laboratory-Confirmed COVID-19 Human Cases among Employees.', 'Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.', 'COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.', 'Degenerate CD8 Epitopes Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out From the SARS-CoV-2 Variants Storm.', 'Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience.', 'Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.', 'CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma.', 'A combined strategy to detect plasma samples reliably with high anti-SARS-CoV-2 neutralizing antibody titers in routine laboratories.', 'Two novel SARS-CoV-2 surrogate virus neutralization assays are suitable for assessing successful immunization with mRNA-1273.', 'E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies.', 'Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients.', 'Analytical and clinical performance of cPass neutralizing antibodies assay.', 'Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma.', 'Limited and Short-Lasting Virus Neutralizing Titers Induced by Inactivated SARS-CoV-2 Vaccine.', 'Synthetic SARS-CoV-2 Spike-Based DNA Vaccine Elicits Robust and Long-Lasting Th1 Humoral and Cellular Immunity in Mice.', 'SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms.', 'Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?', 'Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study.', 'An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope.', 'A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19.', 'Differentiation of immortalized human multi-lineage progenitor to alveolar type 2-like cells: angiotensin-converting enzyme 2 expression and binding of severe acute respiratory syndrome coronavirus 2 spike and spike 1 proteins.', 'Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection.', 'Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients.', 'Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques.', 'Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.', 'Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.', 'Impact of rituximab on COVID-19 outcomes.', 'Correlation of sample-to-cut-off ratio of anti-SARS-CoV-2 IgG antibody chemiluminescent assay with neutralization activity: a prospective multi-centric study in India.', 'Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.', 'A surrogate cell-based SARS-CoV-2 spike blocking assay.', 'Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy.', 'The in\\xa0vitro and in\\xa0vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2.', 'COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models.', 'The SARS-CoV-2-neutralizing capacity of kidney transplant recipients 4 weeks after receiving a second dose of the BNT162b2 vaccine.', 'Detection of SARS-CoV-2-independent immunoregulatory activity of COVID-19 convalescent plasma.', 'Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants.', 'Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation.', 'Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.', 'Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates.', 'Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection.', 'Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display.', 'Assessment of the binding interactions of SARS-CoV-2 spike glycoprotein variants.', 'Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs.', 'High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.', 'A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.', 'Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2.', 'Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants.', 'Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins.', 'Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination.', 'Potent neutralizing RBD-specific antibody cocktail against SARS-CoV-2 and its mutant.', 'Accelerated antibody discovery targeting the SARS-CoV-2 spike protein for COVID-19 therapeutic potential.', 'The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.', 'The First Chemically-Synthesised, Highly Immunogenic Anti-SARS-CoV-2 Peptides in DNA Genotyped ', 'Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.', 'Saliva-Based ELISAs for Effective SARS-CoV-2 Antibody Monitoring in Vaccinated Individuals.', 'Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.', 'Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile.', 'Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.', 'SARS-CoV-2 neutralizing antibodies decline over one year and patients with severe COVID-19 pneumonia display a unique cytokine profile.', 'Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection.', 'Low Environmental Temperature Exacerbates Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Golden Syrian Hamsters.', 'SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.', 'The biological and clinical significance of emerging SARS-CoV-2 variants.', 'A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies.', 'Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.', 'COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.', 'Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection.', 'Obesity Enhances Disease Severity in Female Mice Following West Nile Virus Infection.', 'A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels.', 'Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19.', 'Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study.', 'Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients.', 'Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.', 'Dynamic Interactions of Fully Glycosylated SARS-CoV-2 Spike Protein with Various Antibodies.', 'Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease.', 'Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study.', 'Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.', 'Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters.', 'SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.', 'Genetic drift in the genome of SARS COV-2 and its global health concern.', 'Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.', 'Should the world collaborate imminently to develop neglected live-attenuated vaccines for COVID-19?', 'Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.', 'Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines.', 'COVID-19 Vaccines: Speedy Development and their Use to be Saviour of Humanity.', 'Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19.', 'Neglected roles of IgG Fc-binding protein secreted from airway mucin-producing cells in protecting against SARS-CoV-2 infection.', 'Immune response variables and viral mutations impact on COVID-19 reinfection and relapse.', 'N-Terminal Modification of Gly-His-Tagged Proteins with Azidogluconolactone.', 'SARS-CoV-2 Variant Antibodies Wane 6 Months After Vaccination.', 'Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern.', 'Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity.', 'Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.', 'A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine.', 'Acute exercise increases immune responses to SARS CoV-2 in a previously infected man.', 'A novel IgM intranasal intervention against SARS-CoV-2.', 'Methods to Identify Immunogenic Peptides in SARS-CoV-2 Spike and Protective Monoclonal Antibodies in COVID-19 Patients.', 'Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS-CoV-2 Variants.', 'Probing the Increased Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 (Indian Variant) From Predicted Spike Protein Structure.', 'SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic.', 'Recombinant ', 'Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans.', 'How do I… facilitate a rapid response to a public health emergency requiring plasma collection with a public-private partnership?', 'Decline of antibody titres 3\\xa0months after two doses of BNT162b2 in non-immunocompromised adults.', 'Neutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients.', 'A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site.', 'SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients.', 'The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice.', 'Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study.', 'Possible Link between Higher Transmissibility of Alpha, Kappa and Delta Variants of SARS-CoV-2 and Increased Structural Stability of Its Spike Protein and hACE2 Affinity.', 'Contamination of Hospital Surfaces with Bacterial Pathogens under the Current COVID-19 Outbreak.', 'Deamidation drives molecular aging of the SARS-CoV-2 spike protein receptor-binding motif.', 'Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters.', 'Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals.', 'Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.', 'A novel competition ELISA for the rapid quantification of SARS-CoV-2 neutralizing antibodies in convalescent plasma.', 'Long-Term Persistence and Relevant Therapeutic Impact of High-Titer Viral-Neutralizing Antibody in a Convalescent COVID-19 Plasma Super-Donor: A Case Report.', 'Neutralizing antibodies for the prevention and treatment of COVID-19.', 'Advancements in detection of SARS-CoV-2 infection for confronting COVID-19 pandemics.', 'A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2.', 'Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines-Selecting Compounds for Clinical Evaluation in Coronavirus Disease 2019 Clinical Trials.', 'Vaccines efficacy to SARS-CoV-2 variants require holistic knowledge of viral immunology and protein biochemistry.', 'Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation.', 'A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern ', 'Erratum for Markmann et al., \"Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals\".', 'Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development.', 'Prediction of vaccine efficacy of the Delta variant.', 'Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles.', 'Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity reduces lung inflammation.', 'Epistasis at the SARS-CoV-2 RBD Interface and the Propitiously Boring Implications for Vaccine Escape.', 'Distinct neutralizing kinetics and magnitudes elicited by different SARS-CoV-2 variant spikes.', 'Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation.', 'Perspectives on administration of COVID-19 vaccine to pregnant and lactating women: a challenge for low- and middle-income countries.', 'Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine.', 'Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection.', 'Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants.', 'Trivalent Subunit Vaccine Candidates for COVID-19 and Their Delivery Devices.', 'SARS-CoV-2 Antibody Response to the BNT162b2 mRNA Vaccine in Persons with Past Natural Infection.', 'Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: A case report.', 'Detection of Anti-SARS-CoV-2-S2 IgG Is More Sensitive Than Anti-RBD IgG in Identifying Asymptomatic COVID-19 Patients.', 'Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.', 'Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity.', 'SARS-CoV-2 leads to myocardial injury in rhesus macaque.', 'Animal experiments show impact of vaccination on reduction of SARS-CoV-2 virus circulation: A model for vaccine development?', 'A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.', 'Antibody seroprevalence and rate of asymptomatic infections with SARS-CoV-2 in Austrian hospital personnel.', 'Impact of the Delta variant on vaccine efficacy and response strategies.', 'SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.', 'Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience.', 'Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2.', 'Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies.', 'Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose.', 'SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1.', 'A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope.', 'SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors.', 'Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccine.', 'Structure-based analyses of neutralization antibodies interacting with naturally occurring SARS-CoV-2 RBD variants.', 'Current status of therapeutic monoclonal antibodies against SARS-CoV-2.', 'Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement.', 'Neutrophils and lymphopenia, an unknown axis in severe COVID-19 disease.', 'Measuring accuracy of the neutralizing activity of COVID-19 convalescent plasma.', 'Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection.', 'Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques.', 'Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.', 'AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories.', 'Long-term persistence of neutralizing SARS-CoV-2 antibodies in pets.', 'A Hemagglutination-Based Semiquantitative Test for Point-of-Care Determination of SARS-CoV-2 Antibody Levels.', 'Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.', 'Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.', 'SARS-CoV-2 Spike Protein Mutations and Escape from Antibodies: A Computational Model of Epitope Loss in Variants of Concern.', 'Longitudinal Assessment of Antisevere Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019.', 'Liver transplantation from active COVID-19 donors: A lifesaving opportunity worth grasping?', 'Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity.', 'Phylogenicity of B.1.1.7 surface glycoprotein, novel distance function and first report of V90T missense mutation in SARS-CoV-2 surface glycoprotein.', 'Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses.', 'Mechanical activation of spike fosters SARS-CoV-2 viral infection.', 'Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice.', 'Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies.', 'The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.', 'A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants.', 'Illuminating the Fc dependence of SARS-CoV-2 neutralization.', 'Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19.', 'mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern.', 'Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.', 'Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains.', 'Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2.', 'Evidence of neutralizing antibodies against SARS-CoV-2 in domestic cats living with owners with a history of COVID-19 in Lima - Peru.', 'Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history.', 'Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor.', 'SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity.', 'Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.', 'Associations of SARS-CoV-2 serum IgG with occupation and demographics of military personnel.', 'Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.', 'Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter.', 'Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test.', 'A vaccine based on the receptor-binding domain of the spike protein expressed in glycoengineered ', 'A decoy strategy to activate the immune system.', 'First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19.', 'Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.', 'Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests.', 'CoronaVac induces lower neutralising activity against variants of concern than natural infection.', 'Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis.', 'Multiplex assessment of SARS-CoV-2 antibodies improves assay sensitivity and correlation with neutralizing antibodies.', 'Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy.', 'Rapid induction of antigen-specific CD4', 'Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients.', 'Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.', 'Peptide Platform as a Powerful Tool in the Fight against COVID-19.', 'Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates.', 'Serological Screening for Antibodies against SARS-CoV-2 in Dutch Shelter Cats.', 'Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia.', 'Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice.', 'COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors.', 'Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses.', 'Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population.', 'Intravenous, Intratracheal, and Intranasal Inoculation of Swine with SARS-CoV-2.', 'Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.', 'SARS-CoV-2 Infection in Dogs and Cats from Southern Germany and Northern Italy during the First Wave of the COVID-19 Pandemic.', 'Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.', 'Recombinant Antigens Based on Non-Glycosylated Regions from RBD SARS-CoV-2 as Potential Vaccine Candidates against COVID-19.', 'Virus-Induced CD8', 'Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains.', 'mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects.', 'Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination.', 'Efficient Maternal to Neonate Transfer of Neutralizing Antibodies after SARS-CoV-2 Vaccination with BNT162b2: A Case-Report and Discussion of the Literature.', 'The Efficacy of COVID-19 Vaccines in Chronic Kidney Disease and Kidney Transplantation Patients: A Narrative Review.', 'Impact of Low-Dose Methotrexate-Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis.', 'Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge.', 'DNA Vaccine Administered by Cationic Lipoplexes or by In Vivo Electroporation Induces Comparable Antibody Responses against SARS-CoV-2 in Mice.', 'Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review.', 'Analysis of Host Immunological Response of Adenovirus-Based COVID-19 Vaccines.', 'Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers.', 'Cellular and Humoral Immunogenicity of a Candidate DNA Vaccine Expressing SARS-CoV-2 Spike Subunit 1.', 'Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines.', 'Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera.', 'Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection.', 'An Autochthonous Outbreak of the SARS-CoV-2 P.1 Variant of Concern in Southern Italy, April 2021.', 'Attenuated activation of pulmonary immune cells in mRNA-1273-vaccinated hamsters after SARS-CoV-2 infection.', 'The rapid adaptation of SARS-CoV-2-rise of the variants: transmission and resistance.', 'Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum.', 'Small Structural Proteins E and M Render the SARS-CoV-2 Pseudovirus More Infectious and Reveal the Phenotype of Natural Viral Variants.', 'Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.', 'SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes.', 'Quantitative SARS-CoV-2 Spike Antibody Response in COVID-19 Patients Using Three Fully Automated Immunoassays and a Surrogate Virus Neutralization Test.', 'Comparison of SARS-CoV-2- and HCoV-Specific T Cell Response Using IFN-γ ELISpot.', 'Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers.', 'The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections.', 'Molecular Dynamics Simulation Study of the Interaction between Human Angiotensin Converting Enzyme 2 and Spike Protein Receptor Binding Domain of the SARS-CoV-2 B.1.617 Variant.', 'Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1.', 'An easy method for developing fusion enabled SARS-CoV2 virus fusion mimic (SCFM), bypassing the need of Bio Safety Level (BSL) facility.', 'Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants.', '[Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses].', 'Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals.', 'Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.', 'Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern.', 'Intranasal vaccination.', 'Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York.', 'An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates.', 'SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment.', 'Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies.', 'Effectiveness of Convalescent Plasma Therapy in Severe or Critically Ill COVID-19 Patients: A Retrospective Cohort Study.', 'Serological survey of SARS-CoV-2 incidence conducted at a rural West Virginia hospital.', 'Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates.', 'Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant.', 'Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries.', 'Non-neutralizing SARS CoV-2 directed polyclonal antibodies demonstrate cross-reactivity with the HA glycans of influenza virus.', 'Semi-quantitative, high throughput analysis of SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune response antibodies post infection/vaccination.', 'SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity.', 'Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion.', 'Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects.', 'SARS-CoV-2-reactive T-cell receptors isolated from convalescent COVID-19 patients confer potent T-cell effector function.', 'Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.', 'The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.', 'Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.', 'Characterization of SARS-CoV-2 worldwide transmission based on evolutionary dynamics and specific viral mutations in the spike protein.', 'Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.', 'mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.', 'SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.', 'Assessment of adjuvantation strategy of lipid squalene nanoparticles for enhancing the immunogenicity of a SARS-CoV-2 spike subunit protein against COVID-19.', 'Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.', 'One-shot identification of SARS-CoV-2\\xa0S RBD escape mutants using yeast screening.', 'Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity.', 'Dynamics of viral RNA load, virus culture, seroconversion & infectivity in COVID-19 patients: Implications on isolation policy.', 'Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan.', 'N439K Variant in Spike Protein Alter the Infection Efficiency and Antigenicity of SARS-CoV-2 Based on Molecular Dynamics Simulation.', 'Rarely Recognized Antibody Diversification in Covid-19 Evolution to Counteract Advanced SARS-CoV-2 Evasion Strategies, and Implications for Prophylactic Treatment.', 'Activation or exhaustion of CD8', 'Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: preliminary results.', 'Evolving threat.', 'Autoantibodies neutralizing type I IFNs are present in ', 'Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals.', 'COVID-19: the CaMKII-like system of S protein drives membrane fusion and induces syncytial multinucleated giant cells.', 'The Emergence and Spread of Novel SARS-CoV-2 Variants.', 'Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection.', 'Audio Interview: Aspects of Covid-19 Immunity.', 'Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors.', 'Early Convalescent Plasma for High-Risk Outpatients with Covid-19.', 'Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019.', 'A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants.', 'Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery.', 'Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.', '[Distribution and infectious characteristics of re-positive cases infected with SARS-CoV-2].', 'Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2.', 'The theory and practice of the viral dose in neutralization assay: Insights on SARS-CoV-2 \"doublethink\" effect.', 'Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry.', 'Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial.', 'Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants.', 'Delayed neutralizing antibody response in the acute phase correlates with severe progression of COVID-19.', 'Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action.', 'Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1', 'Controversy surrounding the Sputnik V vaccine.', 'Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2.', 'Nature and Dimensions of Systemic Hyperinflammation and its Attenuation by Convalescent Plasma in Severe COVID-19.', 'Subcutaneous injection of mRNA vaccines against severe acute respiratory syndrome coronavirus 2: an option for severe bleeding disorders or anticoagulated patients?', 'Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers.', 'Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein.', 'Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizers.', 'Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease.', 'SARS-CoV-2 Spike Protein Extrapolation for COVID Diagnosis and Vaccine Development.', 'Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.', 'Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19.', 'Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).', 'Persistence of immunity to SARS-CoV-2 over time in the ski resort Ischgl.', 'Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients.', 'Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.', 'Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.', 'B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.', 'Track-etched membrane microplate and smartphone immunosensing for SARS-CoV-2 neutralizing antibody.', 'Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response.', 'GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.', 'Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function.', 'Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo.', 'Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.', 'Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?', 'Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2.', 'Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People.', 'Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.', 'Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.', 'Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies.', 'A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters.', 'Cross-neutralization of RBD mutant strains of SARS-CoV-2 by convalescent patient derived antibodies.', 'Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A\\xa0phase\\xa01 randomized clinical trial.', 'Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.', 'Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients.', 'The use of pseudotyped coronaviruses for the screening of entry inhibitors: Green tea extract inhibits the entry of SARS-CoV-1, MERS-CoV, and SARS-CoV-2 by blocking receptor-spike interaction.', 'A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2.', 'SARS-CoV-2 Viremia is Associated with COVID-19 Severity and Predicts Clinical Outcomes.', 'Oldest Adults Need 2 mRNA Vaccine Doses to Neutralize SARS-CoV-2.', 'Antibodies to SARS-CoV-2 in dogs and cats, USA.', 'Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals.', '', 'Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern.', 'Two-dimensional multiplexed assay for rapid and deep SARS-CoV-2 serology profiling and for machine learning prediction of neutralization capacity.', 'Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics.', 'SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses.', 'Seroprevalence of SARS-CoV-2 Binding and Neutralizing Antibodies in Healthcare Workers during the Epidemic Peak in Referral Hospitals and Quarantine Sites: Saudi Arabia.', 'Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity.', 'Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2.', 'Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients.', 'Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives.', 'Both SARS-CoV-2 infection and vaccination in pregnancy elicited neutralizing antibodies in pregnant women and newborns.', 'Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine.', 'Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls.', 'Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2.', 'Case Report: Infection With SARS-CoV-2 in the Presence of High Levels of Vaccine-Induced Neutralizing Antibody Responses.', 'Predicting the Severity of Disease Progression in COVID-19 at the Individual and Population Level: A Mathematical Model.', 'CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines ', \"Differential Association of Viral Dynamics With Disease Severity Depending on Patients' Age Group in COVID-19.\", 'Assessment of the potentially decreased neutralizing activities of intravenous immunoglobulin against future coronavirus variants.', 'Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses.', 'Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.', 'One Year after Mild COVID-19: The Majority of Patients Maintain Specific Immunity, But One in Four Still Suffer from Long-Term Symptoms.', 'A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants.', 'Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms.', 'Single-reaction multi-antigen serological test for comprehensive evaluation of SARS-CoV-2 patients by flow cytometry.', 'Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants.', 'Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2.', 'Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations.', 'Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection.', 'A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model.', 'Dynamic Characteristic Analysis of Antibodies in Patients With COVID-19: A 13-Month Study.', 'COVID vaccine boosters: the most important questions.', 'Inhibition of elastase enhances the adjuvanticity of alum and promotes anti-SARS-CoV-2 systemic and mucosal immunity.', 'Detection of neutralizing anti-severe acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with messenger RNA vaccines.', 'Immunity to SARS-CoV-2 induced by infection or vaccination.', 'Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies.', 'Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.', 'Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice.', 'Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies.', 'Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients.', 'Virus antibodies after SARS-CoV-2 infection.', '[Immune memory against SARS-CoV-2: Antibodies against the initial infection and memory B cells for the future ones].', 'Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody.', 'Long-term Persistence of Neutralizing Antibodies to SARS-CoV-2 Following Infection.', 'Inhibition of SARS-CoV-2 pseudovirus invasion by ACE2 protecting and Spike neutralizing peptides: An alternative approach to COVID19 prevention and therapy.', 'Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes.', 'Broad betacoronavirus neutralization by a stem helix-specific human antibody.', 'Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive.', 'Longitudinal observation of antibody responses for 14\\xa0months after SARS-CoV-2 infection.', 'Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view.', 'Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals.', 'The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects.', 'Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction.', 'Protection of human ACE2 transgenic Syrian hamsters from SARS CoV-2 variants by human polyclonal IgG from hyper-immunized transchromosomic bovines.', 'An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory.', 'The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment.', 'Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays.', 'Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection.', 'SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies.', 'The development of ', 'Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report.', 'Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies.', 'SARS-CoV-2 in Transit: Characterization of SARS-CoV-2 Genomes From Venezuelan Migrants in Colombia.', 'Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2.', 'Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike.', 'Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.', 'Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia.', 'Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.', 'Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice.', 'Performance assessment of seven SARS-CoV-2 IgG enzyme-linked immunosorbent assays.', 'Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.', 'A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.', 'SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects.', 'Latent tuberculosis co-infection is associated with heightened levels of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection.', 'Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations.', 'A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine.', 'Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP).', 'Neutralizing antibody responses against SARS-CoV-2 spike receptor-binding domain 13 months after the recovery from the disease.', 'Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19.', 'Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers.', 'The overlooked superpower of mRNA vaccines.', 'Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia.', 'A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding.', 'Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains.', 'A functional assay for serum detection of antibodies against SARS-CoV-2 nucleoprotein.', 'Diagnostic tools for evaluating the effectiveness of COVID 19 vaccines: Challenges and solution.', 'SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.', 'A surrogate virus neutralization test to quantify antibody-mediated inhibition of SARS-CoV-2 in finger stick dried blood spot samples.', 'IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro.', 'Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization.', 'Rapid and stable mobilization of CD8', 'Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.', 'Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.', 'Low mortality in SARS-CoV-2 infected heart transplant recipients at a single center.', 'Überantibodies From Recovered COVID-19 Patients Could Spur New Therapeutics and Vaccines.', 'Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals.', 'Neutralizing SARS-CoV-2 Antibody Response and Protective Effect of 2 Doses of ChAdOx1 nCoV-19 and BBV152 Vaccines in Hemodialysis Patients: A Preliminary Report.', 'Broadly neutralizing anti-coronavirus antibodies.', 'Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries.', 'Assessment of infectivity and the impact on neutralizing activity of immune sera of the COVID-19 variant, CAL.20C.', 'Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.', 'Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.', 'Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants.', 'Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike.', 'Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.', 'ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models.', 'Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.', 'B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.', 'Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques.', 'Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect ', 'Predicting the efficacy of COVID-19 convalescent plasma donor units with the Lumit Dx anti-receptor binding domain assay.', 'Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.', 'Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies.', 'Neutralizing Anti-interferon-γ Autoantibodies: an Ameliorating Factor in COVID-19 Infection?', 'Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose.', 'Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India.', 'Insights into the virologic and immunologic features of SARS-COV-2.', 'SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study.', 'Low Innate Immunity and Lagged Adaptive Immune Response in the Re-Tested Viral RNA Positivity of a COVID-19 Patient.', 'An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity.', 'Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals.', 'A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.', 'Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System.', 'SARS-CoV-2 acquisition and immune pathogenesis among school-aged learners in four diverse schools.', 'Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma.', 'Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study.', 'Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis.', 'Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies.', 'SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.', 'Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics.', 'Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors.', 'Variable Induction of Pro-Inflammatory Cytokines by Commercial SARS CoV-2 Spike Protein Reagents: Potential Impacts of LPS on In Vitro Modeling and Pathogenic Mechanisms In Vivo.', 'Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion.', 'Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2.', 'Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection.', 'A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19.', 'Discrepancy of SARS-CoV-2 PCR results due to the sample collection sites and possible improper sampling.', 'Effects of treatment of COVID-19 with convalescent plasma in 25 B-cell depleted patients.', 'Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination.', 'Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice.', 'Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19.', 'An intranasal vaccine durably protects against SARS-CoV-2 variants in mice.', 'Seroprevalence of SARS-CoV-2 antibodies among rural healthcare workers.', 'Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays.', 'Identification of Human SARS-CoV-2 Monoclonal Antibodies from Convalescent Patients Using EBV Immortalization.', 'Durable Antibody Responses in Staff at Two Long-Term Care Facilities, during and Post SARS-CoV-2 Outbreaks.', 'Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.', 'Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.', 'Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt.', 'Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants.', 'A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters.', 'SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.', 'Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.', 'Vaccine serologic responses among transplant patients associate with COVID-19 infection and T peripheral helper cells.', 'A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates.', \"Xeno-nucleic Acid (XNA) 2'-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding.\", 'Improvement of a SARS-CoV-2 vaccine by enhancing the conjugation efficiency of the immunogen to self-assembled nanoparticles.', 'Broad sarbecovirus neutralization by a human monoclonal antibody.', 'Early antibody responses associated with survival in COVID19 patients.', 'Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+\\xa0T cells in\\xa0cynomolgus\\xa0macaques.', 'Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist.', 'Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.', 'Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals.', 'Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.', 'Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.', '[SARS-CoV-2 variants, a still unfinished story].', 'Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies.', 'A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.', 'Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report.', 'B cell receptor (BCR) guided mechanotransduction: Critical hypothesis to instruct SARS-CoV-2 specific B cells to trigger proximal signalling and antibody reshaping.', 'COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge.', 'SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination.', 'SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence.', 'Free Energy Landscapes from SARS-CoV-2 Spike Glycoprotein Simulations Suggest that RBD Opening Can Be Modulated via Interactions in an Allosteric Pocket.', 'Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19.', 'Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity.', 'Receptor-binding domain recombinant protein RBD219-N1C1 on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.', 'Immunogenicity of low dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates.', 'Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review.', 'Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design.', 'Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2.', 'Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2.', 'A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.', 'Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt.', 'Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.', 'Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.', 'SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.', 'Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.', 'Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.', 'Audio Interview: Monoclonal Antibodies and Vaccine Boosts.', 'Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.', 'SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.', 'Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative.', 'SARS-CoV-2 reinfection in a cancer patient with a defective neutralizing humoral response.', 'Study Suggests Lasting Immunity After COVID-19, With a Big Boost From Vaccination.', 'Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients.', 'Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance.', 'A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma.', 'A French cohort for assessing COVID-19 vaccine responses in specific populations.', 'One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.', 'Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model.', 'Systems vaccinology of the BNT162b2 mRNA vaccine in humans.', 'Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay.', 'Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T\\xa0cells.', 'Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial.', 'COVID-19 Pandemic and the Convalescent Plasma Therapy: Possible Benefits and Risks.', 'Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets.', 'Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.', 'Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.', 'A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.', 'Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model.', 'Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2.', 'Can immune responses predict which vaccines work best?', 'Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study.', 'Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.', 'In\\xa0vitro and in\\xa0vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.', 'Genomic monitoring unveil the early detection of the SARS-CoV-2 B.1.351 (beta) variant (20H/501Y.V2) in Brazil.', 'Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.', 'SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data.', 'Contemporary narrative review of treatment options for COVID-19.', 'Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.', 'Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2.', 'Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.', 'Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.', 'Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.', 'Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis.', 'A facile chemoenzymatic synthesis of SARS-CoV-2 glycopeptides for probing glycosylation functions.', 'Rapid and accurate agglutination-based testing for SARS-CoV-2 antibodies.', 'Detection and Neutralization of SARS-CoV-2 Using Non-conventional Variable Lymphocyte Receptor Antibodies of the Evolutionarily Distant Sea Lamprey.', 'Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies.', 'SARS-CoV-2-specific immune response in COVID-19 convalescent individuals.', 'Seropositive reaction rates of 9 B cell epitopes of the SARS-CoV-2 spike protein and the relationship between the epitopes and neutralizing antibody.', 'The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience.', 'Audio Interview: How Well Are Covid-19 Vaccines Working?', 'Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants.', 'N-terminal domain of SARS CoV-2 spike protein mutation associated reduction in effectivity of neutralizing antibody with vaccinated individuals.', 'Perinatal transmission of SARS-CoV-2 and transfer of maternal IgG/neutralizing anti-SARS-CoV-2 antibodies from mothers with asymptomatic infection during pregnancy.', 'One-year persistence of neutralizing anti-SARS-CoV-2 antibodies in dialysis patients recovered from COVID-19.', 'Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin.', 'Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples.', 'Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain.', 'Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing.', 'Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan.', 'SARS-CoV-2 antibody response dynamics and heterogeneous diagnostic performance of four serological tests and a neutralization test in symptomatic healthcare workers with non-severe COVID-19.', 'Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques.', 'SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants.', 'Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents.', 'Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex).', 'A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus.', 'Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2.', 'Serological response to a single dose of a SARS-CoV-2 mRNA vaccine.', 'BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.', 'SARS-CoV-2 surveillance in Norway rats (Rattus norvegicus) from Antwerp sewer system, Belgium.', 'Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants.', 'SARS-CoV-2: Origin, Evolution, and Targeting Inhibition.', 'Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset.', 'The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.', 'The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom.', 'SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies.', 'Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2.', 'The presence of anti-leucocyte antibodies in the plasma of convalescent women after SARS-CoV-2 infection as a reason for disqualification for plasma therapy - analysis based on a literature review.', 'Assessment of serological assays for identifying high titer convalescent plasma.', 'Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19.', 'Pharmacokinetic profiles of a SARS-COV-2 neutralizing antibody BD-604 in cynomolgus monkeys.', 'Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.', 'Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice.', 'Structure-function relations of the SARS-CoV-2 spike protein and impact of mutations in the variants of concern.', 'StatPearls', 'StatPearls', 'COVID-19: individual and herd immunity.', 'Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation.', 'Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses.', 'Immunological mechanisms of vaccine-induced protection against COVID-19 in humans.', 'Mix-and-match COVID vaccines: the case is growing, but questions remain.', 'SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern.', 'Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.', 'Evidence for antibody as a protective correlate for COVID-19 vaccines.', 'Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience.', 'Use of Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs.', 'More Is Always Better Than One: The N-Terminal Domain of the Spike Protein as Another Emerging Target for Hampering the SARS-CoV-2 Attachment to Host Cells.', 'Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine.', 'Full-Length Computational Model of the SARS-CoV-2 Spike Protein and Its Implications for a Viral Membrane Fusion Mechanism.', 'Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants.', 'BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers.', 'Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?', 'SARS-Cov-2 Natural Infection in a Symptomatic Cat: Diagnostic, Clinical and Medical Management in a One Health Vision.', 'Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals.', 'Different Neutralization Sensitivity of SARS-CoV-2 Cell-to-Cell and Cell-Free Modes of Infection to Convalescent Sera.', 'Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart.', 'SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.', 'Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties.', 'Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination.', 'SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies.', 'Optimization of Vero Cells Grown on a Polymer Fiber Carrier in a Disposable Bioreactor for Inactivated Coxsackievirus A16 Vaccine Development.', 'A Bioluminescent Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and In Vitro.', 'Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans.', 'Titers, Prevalence, and Duration of SARS-CoV-2 Antibodies in a Local COVID-19 Outbreak and Following Vaccination.', 'Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region?', 'Systemic Adverse Events and Use of Antipyretics Predict the Neutralizing Antibody Positivity Early after the First Dose of ChAdOx1 Coronavirus Disease Vaccine.', 'AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC.', 'Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial.', 'Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.', 'Engineered single-domain antibodies tackle COVID variants.', 'CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2.', 'Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity.', 'Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.', 'SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2.', 'Persistence of humoral response upon SARS-CoV-2 infection.', 'Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays.', 'Detection of antibodies neutralizing historical and emerging SARS-CoV-2 strains using a thermodynamically coupled de novo biosensor system.', 'Extracellular vesicles carry SARS-CoV-2 spike protein and serve as decoys for neutralizing antibodies.', 'Prevalence of COVID-19 antibodies among operating room and critical care staff at a tertiary teaching hospital: A cross-sectional study.', 'Targeting neuropilins as a viable SARS-CoV-2 treatment.', 'COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.', 'IgA potentiates NETosis in response to viral infection.', 'A Rapid Assay for SARS-CoV-2 Neutralizing Antibodies That Is Insensitive to Antiretroviral Drugs.', 'SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.', 'An optimized and robust SARS-CoV-2 pseudovirus system for viral entry research.', 'Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assay-Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G Commercial Serology Assays.', 'Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.', 'Serological survey of antibodies against SARS-CoV-2 in dogs and cats, Thailand.', 'A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates.', 'Promising Immunotherapies against COVID-19.', 'Antibody Responses to SARS-CoV-2 Following an Outbreak Among Marine Recruits With Asymptomatic or Mild Infection.', 'Neutralizing Antibodies against SARS-CoV-2 and HLA Class I and II Polymorphism.', 'Detectable SARS-CoV-2 RNAemia in Critically Ill Patients, but Not in Mild and Asymptomatic Infections.', 'Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies.', 'Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2.', 'Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative.', 'Prevalence of SARS-CoV-2 infection and dynamics of antibodies response among previously undiagnosed healthcare workers in a university hospital: A prospective cohort study.', 'A newly identified linear epitope on non-RBD region of SARS-CoV-2 spike protein improves the serological detection rate of COVID-19 patients.', 'Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study.', 'Virological and immunological features of SARS-COV-2 infected children with distinct symptomatology.', 'COVID-19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes.', 'Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis.', 'SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses.', 'Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.', 'Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity.', 'Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants.', 'Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.', 'Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species.', 'Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7.', 'Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience.', 'Persistence of Neutralizing Antibody Response up to 1 Year After Asymptomatic or Symptomatic SARS-CoV-2 Infection.', 'SARS-CoV-2 Serologic Assays Dependent on Dual-Antigen Binding Demonstrate Diverging Kinetics Relative to Other Antibody Detection Methods.', 'Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity.', 'Neutralizing Antibody Responses to SARS-CoV-2 in Korean Patients Who Have Recovered from COVID-19.', 'Longitudinal Antibody Dynamics Against Structural Proteins of SARS-CoV-2 in Three COVID-19 Patients Shows Concurrent Development of IgA, IgM, and IgG.', 'Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.', 'Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques.', 'Comparison of two assays to detect IgG antibodies to the receptor binding domain of SARS‑CoV‑2 as a surrogate marker for assessing neutralizing antibodies in COVID-19 patients.', 'Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.', 'The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.', 'Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies.', 'Local memory CD4 T cell niches in respiratory viral infection.', 'Recent advances in antibody-based immunotherapy strategies for COVID-19.', 'Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses.', 'Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease.', 'Protective efficacy of rhesus adenovirus COVID-19 vaccines against mouse-adapted SARS-CoV-2.', 'A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters.', 'Mild SARS-CoV-2 Infections and Neutralizing Antibody Titers.', 'Strong SARS-CoV-2-neutralizing antibody response of previously-infected healthcare workers given one dose of mRNA vaccine.', 'Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain.', 'In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.', 'Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection.', 'Kinetics of Anti-SARS-CoV-2 IgG among healthcare workers in a General Hospital.', 'Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity.', 'Production of the Receptor-binding Domain of the Viral Spike Proteins from 2003 and 2019 SARS CoVs and the Four Common Human Coronaviruses for Serologic Assays and Inhibitor Screening.', 'Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.', 'Rational optimization of a human neutralizing antibody of SARS-CoV-2.', 'One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection.', 'COVID-19 antibody donation using immunoadsorption: Report of two cases.', 'COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era.', 'CureVac COVID vaccine let-down spotlights mRNA design challenges.', 'Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.', 'Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19.', 'Purification and characterization of the receptor-binding domain of SARS-CoV-2 spike protein from ', 'Characterization of a new SARS-CoV-2 variant that emerged in Brazil.', 'An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.', 'Early and High SARS-CoV-2 Neutralizing Antibodies Are Associated with Severity in COVID-19 Patients from India.', 'Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay.', 'Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection.', 'Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers.', 'Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19.', 'Humoral and cellular immune responses against SARS-CoV-2 variants and human coronaviruses after single BNT162b2 vaccination.', 'A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T\\xa0cell responses.', 'Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.', 'Human IgG and IgA responses to COVID-19 mRNA vaccines.', 'Spike Protein Antibodies Mediate the Apparent Correlation between SARS-CoV-2 Nucleocapsid Antibodies and Neutralization Test Results.', 'SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques.', 'Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections.', 'Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry.', 'SARS-CoV-2 infection and transmission in the North American deer mouse.', 'AI-guided discovery of the invariant host response to viral pandemics.', 'Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.', 'Seroprevalence of SARS-CoV-2 (COVID-19) exposure in pet cats and dogs in Minnesota, USA.', 'Extracellular Vesicle Capture by AnTibody of CHoice and Enzymatic Release (EV-CATCHER): A customizable purification assay designed for small-RNA biomarker identification and evaluation of circulating small-EVs.', 'Prospects of Neutralizing Nanobodies Against SARS-CoV-2.', 'Potent and Persistent Antibody Response in COVID-19 Recovered Patients.', 'SARS-CoV-2 antibody persistence in COVID-19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance.', 'Phenotypes and Functions of SARS-CoV-2-Reactive T Cells.', 'Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models.', 'Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant.', 'Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination.', 'Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant.', 'COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men.', 'SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung.', 'Analysis of the molecular mechanism of SARS-CoV-2 antibodies.', 'Can We AlphaFold Our Way Out of the Next Pandemic?', 'Validation of high-throughput, semiquantitative solid-phase SARS\\xa0coronavirus-2 serology assays in serum and dried blood spot matrices.', 'BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.', 'Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.', 'Corona Virus Disease-19 serology, inflammatory markers, hospitalizations, case finding, and aging.', 'The need for and challenges of comparing SARS-CoV-2 antibody assays.', 'Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model.', 'Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays.', 'Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.', 'Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. Reply.', 'Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.', 'Identification and evaluation of the inhibitory effect of Prunella vulgaris extract on SARS-coronavirus 2 virus entry.', 'Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response.', 'Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection.', 'An Overview About the Role of Adaptive Immunity in Keeping SARS-CoV-2 Reinfections at Bay.', '\"Nanotraps\" Designed to Capture and Clear SARS-CoV-2.', 'Be aware of SARS-CoV-2 spike protein: There is more than meets the eye.', 'Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.', 'Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination.', 'Immune transcriptomes from hospitalized patients infected with the SARS-CoV-2 variants B.1.1.7 and B.1.1.7 carrying the E484K escape mutation.', 'Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients.', 'Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination.', 'Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking.', 'Functional characterization of SARS-CoV-2 vaccine elicited antibodies in immunologically naïve and pre-immune humans.', 'Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year.', 'SARS-CoV-2 Spreads through Cell-to-Cell Transmission.', 'SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care.', 'Breakthrough COVID-19 case after full-dose administration of CoronaVac vaccine.', 'Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.', 'SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity.', 'Comparative immunogenicity analysis of intradermal versus intramuscular administration of SARS-CoV-2 RBD epitope peptide-based immunogen In\\xa0vivo.', 'A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351.', 'How we secured a COVID-19 convalescent plasma procurement scheme in Japan.', 'Protocol for constructing large size human antibody heavy chain variable domain (V', 'Can We Protect Those We Care for in A Pandemic? - Prevalence of Neutralizing Antibodies against SARS-CoV-2 in Nursing Homes.', 'Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.', 'History repeats itself: horse originated hyperimmune sera production against SARS CoV-2', 'Colloidal gold immunochromatographic assay (GICA) is an effective screening method for identifying detectable anti-SARS-CoV-2 neutralizing antibodies.', 'Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.', 'Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus.', 'Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection.', 'Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2 in humans and mice.', 'Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity.', 'Synthetic proteins for COVID-19 diagnostics.', 'Tackling COVID-19 with neutralizing monoclonal antibodies.', 'Marked Increase in Avidity of SARS-CoV-2 Antibodies 7-8 Months After Infection Is Not Diminished in Old Age.', 'Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.', 'Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.', 'Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern.', 'Evaluation of the performance of SARS--CoV--2 antibody assays for a longitudinal population-based study of COVID--19 spread in St. Petersburg, Russia.', 'Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.', 'IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers.', 'Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.', 'Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity.', 'Evidence of neutralizing antibodies against SARS-CoV-2 in domestic cats living with owners with a history of COVID-19 in Lima - Peru.', 'Divergent early antibody responses define COVID-19 disease trajectories.', 'Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates.', 'Fc-engineered antibody therapeutics with improved efficacy against COVID-19.', 'Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines.', 'Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays.', 'Pregnancy Outcome, Antibodies, and Placental Pathology in SARS-CoV-2 Infection during Early Pregnancy.', 'Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections.', 'Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay.', 'New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection.', 'Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?', 'Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: Introducing SpikePro.', 'Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants.', \"Aptamer BC 007's Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies.\", 'Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice.', 'SARS-CoV-2 Infections and Viral Isolations among Serially Tested Cats and Dogs in Households with Infected Owners in Texas, USA.', 'Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies.', 'Convalescent Plasma Efficacy in Life-Threatening COVID-19 Patients Admitted to the ICU: A Retrospective Cohort Study.', 'Human Milk from Previously COVID-19-Infected Mothers: The Effect of Pasteurization on Specific Antibodies and Neutralization Capacity.', 'Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America.', 'Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein.', 'Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2.', 'Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.', \"Mutation in a SARS-CoV-2 Haplotype from Sub-Antarctic Chile Reveals New Insights into the Spike's Dynamics.\", 'Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1.', 'Human CD4', 'Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.', 'Antibody Responses One Year after Mild SARS-CoV-2 Infection.', 'A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity.', 'Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis.', 'The first Chinese national standards for SARS-CoV-2 neutralizing antibody.', 'Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors.', 'Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine.', 'Covid-19 vaccination in patients with multiple myeloma: Focus on immune response.', 'Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine.', 'Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine.', 'Current Strategies of Antiviral Drug Discovery for COVID-19.', 'SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors.', 'Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac.', 'SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors.', 'Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers.', 'Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates.', \"Correspondence on 'Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.\", 'Are the new SARS-CoV-2 variants resistant against the vaccine?', 'Infection and Immune Memory: Variables in Robust Protection by Vaccines Against SARS-CoV-2.', 'Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.', 'Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses.', '', 'BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.', 'E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil.', 'Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.', 'SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model.', \"Molecular dynamics analysis of N-acetyl-D-glucosamine against specific SARS-CoV-2's pathogenicity factors.\", 'DNA vaccination induced protective immunity against SARS CoV-2 infection in hamsterss.', 'Audio Interview: Protecting the Immunosuppressed against Covid-19.', \"The COVID vaccine pioneer behind southeast Asia's first mRNA shot.\", 'Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2.', \"Increased elastase sensitivity and decreased intramolecular interactions in the more transmissible 501Y.V1 and 501Y.V2 SARS-CoV-2 variants' spike protein-an in silico analysis.\", 'Immune evasion of SARS-CoV-2 variants of concern is driven by low affinity to neutralizing antibodies.', 'Practical guidance for clinical laboratories for SARS-CoV-2 serology testing.', 'Effective high-throughput isolation of fully human antibodies targeting infectious pathogens.', 'Immune response to SARS-CoV-2 variants of concern in vaccinated individuals.', 'SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees.', 'BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response.', 'Antibodies: what makes us stronger.', 'Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection.', 'Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection.', 'SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection.', 'Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines.', 'Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants.', 'Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity.', 'Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2.', 'The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2.', 'Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?', 'SARS-CoV-2 variants: Subversion of antibody response and predicted impact on T\\xa0cell recognition.', 'Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors.', 'Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies.', 'SARS-CoV-2 variants: A double-edged sword?', 'Glycosylation is a key in SARS-CoV-2 infection.', 'SARS-CoV-2 nanobodies 2.0.', 'Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.', 'Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individuals.', 'Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection.', 'Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets.', 'Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines.', 'Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies.', 'Exploring SARS-CoV-2 Spikes Glycoproteins for Designing Potential Antiviral Targets.', 'Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza.', 'Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants.', 'Novel SARS-CoV-2 variants: the pandemics within the pandemic.', 'The COVID-19 vaccine development: A pandemic paradigm.', 'B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV.', 'Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.', 'Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy.', 'SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.', 'Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant.', 'High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.', 'Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response.', 'Dynamic Interactions of Fully Glycosylated SARS-CoV-2 Spike Protein with Various Antibodies.', 'In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.', 'Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient.', 'Systems biological assessment of human immunity to BNT162b2 mRNA vaccination.', 'Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization.', 'Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection.', 'High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies.', 'Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma.', 'Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden.', 'Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.', 'SARS-CoV-2 vaccines: anamnestic response in previously infected recipients.', 'Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins.', 'Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study.', 'Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics.', 'Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine.', 'Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.', 'Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice.', 'Rapid isolation and immune profiling of SARS-CoV-2 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq.', 'Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.', 'Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.', 'Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.', 'Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis.', 'Key residues of the receptor binding domain in the spike protein of SARS-CoV-2 mediating the interactions with ACE2: a molecular dynamics study.', 'A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection.', 'Decay of Fc-dependent antibody functions after mild to moderate COVID-19.', 'A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain.', 'Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.', 'Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates.', '[Susceptibility of animal species to experimental SARS-CoV-2 (', 'Bamlanivimab Use in a Military Treatment Facility.', 'Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV.', 'Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.', 'The Magnitude and Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in Transplant Population Is Similar to the General Population Despite Immunosuppression.', 'Identification of and Surveillance for the SARS-CoV-2 Variants B.1.427 and B.1.429 - Colorado, January-March 2021.', 'Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies.', 'Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein.', 'Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2.', 'Investigation of an outbreak of symptomatic SARS-CoV-2 VOC 202012/01-lineage B.1.1.7 infection in healthcare workers, Italy.', 'Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans.', 'Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.', 'COVID-19 Vaccines in Patients With Cancer-A Welcome Addition, but There Is Need for Optimization.', 'Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study.', 'Structural basis for broad coronavirus neutralization.', 'Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19-Convalescent Donors.', 'A Combined Molecular Docking and Density Functional Theory Nuclear Magnetic Resonance Study of Trans-Dehydrocrotonin Interacting with COVID-19 Main Protease and Severe Acute Respiratory Syndrome Coronavirus 2 3C-Like Protease.', 'Audio Interview: Vaccination and Variants in the U.S. and South Africa.', 'BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.', 'Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor.', 'Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection.', 'A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations.', 'Coronavirus variants are spreading in India - what scientists know so far.', 'A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.', 'Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival.', 'Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?', 'Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia.', 'A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19.', 'A hemagglutination-based, semi-quantitative test for point-of-care determination of SARS-CoV-2 antibody levels.', 'Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination.', 'LY-CoV1404 potently neutralizes SARS-CoV-2 variants.', 'Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals.', 'Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19.', 'Author Correction: Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers.', 'Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein.', 'Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.', 'Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.', 'Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.', 'Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8\\xa0months post-symptom onset.', 'Antibodies and Vaccines Target RBD of SARS-CoV-2.', 'Enhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein Through Structure-Guided Design.', 'Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.', '', 'Current Overviews on COVID-19 Management Strategies.', 'Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions.', 'Pfizer COVID vaccine protects against worrying coronavirus variants.', 'SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses.', 'Performance of Three SARS-CoV-2 Immunoassays, Three Rapid Lateral Flow Tests, and a Novel Bead-Based Affinity Surrogate Test for the Detection of SARS-CoV-2 Antibodies in Human Serum.', 'Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC', 'Antiviral treatment selection for SARS-CoV-2 pneumonia.', 'Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2.', 'Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes.', 'Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease.', 'Maintenance of neutralizing antibodies over ten months in convalescent SARS-CoV-2 afflicted patients.', 'Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1.', 'Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies.', 'SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.', 'Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11.', 'The Contribution of Biophysics and Structural Biology to Current Advances in COVID-19.', 'Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine.', 'SARS-CoV-2 B.1.1.7 variant of concern detected in a pet dog and cat after exposure to a person with COVID-19, USA.', 'Delayed production of neutralizing antibodies correlates with fatal COVID-19.', 'Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys.', 'Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.', 'Is a single COVID-19 vaccine dose enough in convalescents ?', 'Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells.', 'Previously infected vaccinees broadly neutralize SARS-CoV-2 variants.', 'Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.', 'Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity.', 'A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice.', 'Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes.', 'Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients.', 'Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection.', 'Global virus tracker.', 'Comparative Analysis of Antigen-Specific Anti-SARS-CoV-2 Antibody Isotypes in COVID-19 Patients.', 'First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19.', 'Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice.', 'Antibody Responses in COVID-19: A Review.', 'Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19.', 'SARS-CoV-2 immunity and HIV infection: total recall?', 'SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study.', 'The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients.', 'Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2.', 'Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose.', 'Diagnostic accuracy of three SARS-CoV2 antibody detection assays, neutralizing effect and longevity of serum antibodies.', 'A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in\\xa0vitro.', 'A real-time and high-throughput neutralization test based on SARS-CoV-2 pseudovirus containing monomeric infrared fluorescent protein as reporter.', 'Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines.', 'Models to inform neutralizing antibody therapy strategies during pandemics: the case of SARS-CoV-2.', 'Glycans of SARS-CoV-2 Spike Protein in Virus Infection and Antibody Production.', 'Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection.', 'A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response.', 'Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies.', 'Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.', 'AP205 VLPs Based on Dimerized Capsid Proteins Accommodate RBM Domain of SARS-CoV-2 and Serve as an Attractive Vaccine Candidate.', 'SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies.', 'SARS-CoV-2 IgG Antibodies Seroprevalence and Sera Neutralizing Activity in MEXICO: A National Cross-Sectional Study during 2020.', 'A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay.', 'SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus.', 'Household Cases Suggest That Cats Belonging to Owners with COVID-19 Have a Limited Role in Virus Transmission.', 'Longitudinal Analysis and Comparison of Six Serological Assays up to Eight Months Post-COVID-19 Diagnosis.', 'SARS-CoV-2 Seroprevalence among Health Care Workers-A Voluntary Screening Study in a Regional Medical Center in Southern Germany.', 'Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.', 'Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins.', 'The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.', 'Neutralizing Antibody Therapeutics for COVID-19.', 'COVID-19-Importance for Patients on the Waiting List and after Kidney Transplantation-A Single Center Evaluation in 2020-2021.', 'A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model.', 'BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19.', 'Previous Humoral Immunity to the Endemic Seasonal Alphacoronaviruses NL63 and 229E Is Associated with Worse Clinical Outcome in COVID-19 and Suggests Original Antigenic Sin.', 'SARS-CoV-2 serology testing: Progress and challenges.', 'Risk factors for COVID-19 mortality: The effect of convalescent plasma administration.', 'Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies.', 'TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability.', 'Lack of immune response after mRNA vaccination to SARS-CoV-2 in a solid organ transplant patient.', 'Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective.', 'Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic.', 'Innate immune-mediated antiviral response to SARS-CoV-2 and convalescent sera a potential prophylactic and therapeutic agent to tackle COVID-19.', 'Human neutralizing antibodies to SARS-CoV-2: views and perspectives from Professor Linqi Zhang at Tsinghua University.', 'Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy.', 'Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes.', 'Maternal Antibody Response, Neutralizing Potency, and Placental Antibody Transfer After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.', 'Investigation of SARS-CoV-2 infection in dogs and cats of humans diagnosed with COVID-19 in Rio de Janeiro, Brazil.', 'Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein.', 'Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and \"Reopening\".', 'Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections.', 'Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.', 'Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.', 'Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques.', 'Differences in seroprevalence between epicenter and non-epicenter areas of the COVID-19 outbreak in South Korea.', 'Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents.', 'Insertions in SARS-CoV-2 genome caused by template switch and duplications give rise to new variants of potential concern.', 'A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope.', 'Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates.', 'Comparative Analysis of Emerging B.1.1.7+E484K SARS-CoV-2 isolates from Pennsylvania.', 'Nanotraps for the containment and clearance of SARS-CoV-2.', 'Construction and applications of SARS-CoV-2 pseudoviruses: a mini review.', 'Development and application of therapeutic antibodies against COVID-19.', 'Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination.', 'Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.', 'A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics.', 'Monoclonal antibody therapy in COVID-19.', 'NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies.', 'Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike.', 'Experimental Identification of Immuno- dominant B-cell Epitopes from SARS-CoV-2.', 'COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?', 'SARS-CoV-2 inactivated vaccine (Vero cells) shows good safety in repeated administration toxicity test of Sprague Dawley rats.', 'Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations.', 'A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System.', 'Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.', 'Comparison of virus neutralization activity and results of 10 different anti-SARS-CoV-2 serological tests in COVID-19 recovered plasma donors.', 'Antibodies for COVID-19 - which, when and how long?', 'Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19.', 'A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection.', 'Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.', 'Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays.', 'The basis of a more contagious 501Y.V1 variant of SARS-CoV-2.', 'Structure and function analysis of a potent human neutralizing antibody CA521', 'Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.', 'Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera.', 'Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1.', 'A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters.', 'Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis.', 'IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection.', 'Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.', 'CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge.', 'SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity.', 'Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment.', 'Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won.', 'Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.', 'Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.', 'Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization.', 'Intradermal delivery of a synthetic DNA vaccine protects macaques from Middle East respiratory syndrome coronavirus.', 'Binding of the SARS-CoV-2 Spike Protein to the Asialoglycoprotein Receptor on Human Primary Hepatocytes and Immortalized Hepatocyte-Like Cells by Confocal Analysis.', 'Vaccine Breakthrough Infections with SARS-CoV-2 Variants.', 'Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization.', 'Intermolecular Interaction Analyses on SARS-CoV-2 Spike Protein Receptor Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor-Blocking Antibody/Peptide Using Fragment Molecular Orbital Calculation.', 'Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells.', 'StatPearls', 'StatPearls', 'LiverTox: Clinical and Research Information on Drug-Induced Liver Injury', 'Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants.', 'The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD.', 'An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory.', 'Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.', 'COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions.', 'Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.', 'Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!', 'Design and application of nanoparticles as vaccine adjuvants against human corona virus infection.', 'Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2.', 'Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum.', 'Neutralizing monoclonal antibodies for treatment of COVID-19.', 'Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models.', 'Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.', 'Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial.', 'Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses.', 'SARS-CoV-2 antibodies: Comparison of three high-throughput immunoassays versus the neutralization test.', 'RBD-specific polyclonal F(ab´)', 'Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay.', 'The SARS-CoV-2 Spike variant D614G favors an open conformational state.', 'Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.', 'Wuhan to World: The COVID-19 Pandemic.', 'Generation of recombinant hyperimmune globulins from diverse B-cell repertoires.', 'The dream vaccine.', 'Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination.', 'Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination.', 'SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization.', 'Decreased Use of Broad-Spectrum Antibiotics During the Coronavirus Disease 2019 Epidemic in South Korea.', 'Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers.', 'Progress in research on the S protein as the target of COVID-19 vaccines.', 'Antibody evasion by the P.1 strain of SARS-CoV-2.', 'SARS-CoV-2 Antibody Response in Persons with Past Natural Infection.', 'Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies.', 'Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain.', 'Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019.', 'Predicting the severity of disease progression in COVID-19 at the individual and population level: A mathematical model.', 'Neutralization of SARS-CoV-2 variants by convalescent and vaccinated serum.', 'Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2.', 'Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody.', 'Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity.', 'Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality.', 'SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques.', 'Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.', 'Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape.', 'Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.', 'Early T\\xa0cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset.', 'A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.', 'SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice.', 'SARS-CoV-2 mutations: A strain on efficacy of neutralizing monoclonal antibodies?', 'Correlates of protection from SARS-CoV-2 infection.', 'Clinical characteristics and plasma antibody titer of patients with COVID-19 in Zhejiang, China.', 'Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19.', 'SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses.', 'Rapid lateral flow tests for the detection of SARS-CoV-2 neutralizing antibodies.', 'Structure-based Design of a Specific, Homogeneous Luminescence Enzyme Reporter Assay for SARS-CoV-2.', 'Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.', 'Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine.', 'Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.', 'Capturing Cytokines with Advanced Materials: A Potential Strategy to Tackle COVID-19 Cytokine Storm.', 'Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates.', 'Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany.', 'Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.', 'Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2.', 'Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology.', 'Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates.', 'COVID-19 serology in nephrology healthcare workers.', \"Insights into SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival.\", 'Latest Russian vaccine comes with a big dose of mystery.', 'SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms.', 'A human coronavirus evolves antigenically to escape antibody immunity.', 'Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort.', 'SARS-CoV-2 show no infectivity at later stages in a prolonged COVID-19 patient despite positivity in RNA testing.', 'Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors.', 'A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2.', 'Transmission and Protection against Reinfection in the Ferret Model with the SARS-CoV-2 USA-WA1/2020 Reference Isolate.', 'A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients.', 'Audio Interview: Antibody Responses to Natural Infection and Vaccination.', 'Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.', 'Preparing for the Future - Nanobodies for Covid-19?', 'Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).', 'Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2.', 'Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster.', 'CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity.', 'A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.', 'A novel anti-human IL-1R7 antibody reduces IL-18-mediated inflammatory signaling.', 'Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.', 'Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.', 'Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.', 'SARS-CoV-2 immune evasion by variant B.1.427/B.1.429.', 'Analysis of glycosylation and disulfide bonding of wild-type SARS-CoV-2 spike glycoprotein.', 'Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2.', 'A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes.', 'Recovery from acute SARS-CoV-2 infection and development of anamnestic immune responses in T cell-depleted rhesus macaques.', 'Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 golden Syrian hamster model.', 'The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.', 'Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape.', 'Use of convalescent plasma for COVID-19 in India: A review & practical guidelines.', 'Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19.', 'SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex\\xa0vivo ELISpot assay.', 'Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers.', 'Peripheral Plasma Cells Associated with Mortality Benefit in Severe COVID-19: A Marker of Disease Resolution.', 'Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope.', 'Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.', 'SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines.', 'Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG.', 'SARS-CoV-2 Infection and Antibody Response in a Symptomatic Cat from Italy with Intestinal B-Cell Lymphoma.', 'Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test.', 'Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice.', 'Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates.', 'Endogenously Produced SARS-CoV-2 Specific IgG Antibodies May Have a Limited Impact on Clearing Nasal Shedding of Virus during Primary Infection in Humans.', 'SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations.', 'Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications.', 'Detection and Genome Sequencing of SARS-CoV-2 in a Domestic Cat with Respiratory Signs in Switzerland.', 'Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies.', 'Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2.', 'Towards Quantitative and Standardized Serological and Neutralization Assays for COVID-19.', 'Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19.', 'Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.', 'Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant.', 'Pregnancy alters interleukin-1 beta expression and antiviral antibody responses during severe acute respiratory syndrome coronavirus 2 infection.', 'Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.', 'Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.', 'Systems serology detects functionally distinct coronavirus antibody features in children and elderly.', 'Designed proteins assemble antibodies into modular nanocages.', 'Development and Validation of a Multiplex Microsphere Immunoassay Using Dried Blood Spots for SARS-CoV-2 Seroprevalence: Application in First Responders in Colorado, USA.', 'Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class.', 'SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.', 'Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine.', 'Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient.', 'T-cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibody titers and disease severity.', 'SARS-CoV-2 Acquisition and Immune Pathogenesis Among School-Aged Learners in Four Diverse Schools.', 'Assessment of serological assays for identifying high titer convalescent plasma.', 'Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants.', 'Live Imaging of SARS-CoV-2 Infection in Mice Reveals Neutralizing Antibodies Require Fc Function for Optimal Efficacy.', 'B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies.', 'A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants.', 'Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates.', 'Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects.', 'Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.', 'Longitudinal dynamics of antibody responses in recovered COVID-19 patients.', 'SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera.', 'Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite.', 'A comparative review of immunoassays for COVID-19 detection.', 'Convalescent plasma treatment of critically ill intensive care COVID-19 patients.', 'Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms.', 'Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.', 'Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment.', 'B Cell Response to Vaccination.', 'Case Report: A Severe SARS-CoV-2 Infection in a Teenager With Angelman Syndrome.', 'Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design.', 'Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.', 'Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen.', 'Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection.', 'Engineered Ultra-High Affinity Synthetic Antibodies for SARS-CoV-2 Neutralization and Detection.', 'The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein.', 'COVID-19 vaccines: A race against time.', 'Molecular characterization of interactions between the D614G variant of SARS-CoV-2\\xa0S-protein and neutralizing antibodies: A computational approach.', 'Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.', 'A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.', 'Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2.', 'Associating SARS-CoV-2 Serological Assays with Protection: Where the Field Stands.', 'Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.', 'IgV somatic mutation of human anti-SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity.', 'The evolutionary dynamics of endemic human coronaviruses.', 'The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic.', 'What it will take to vaccinate the world against COVID-19.', 'Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice.', 'mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.', 'The emerging plasticity of SARS-CoV-2.', 'Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.', 'Neutralizing antibodies for SARS-CoV-2 in stray animals from Rio de Janeiro, Brazil.', 'The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients.', 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.', 'N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.', 'Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients.', 'New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications.', 'JMM Profile: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).', 'SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses.', 'Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation.', 'Anti-SARS-CoV-2 Serology persistence over time in COVID-19 Convalescent Plasma Donors.', 'The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD.', 'Functional Antibodies in COVID-19 Convalescent Plasma.', 'A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.', 'Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies.', 'Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants.', 'A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses.', 'Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies.', 'Rationally designed immunogens enable immune focusing to the SARS-CoV-2 receptor binding motif.', 'Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes.', 'One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening.', 'ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.', 'Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva.', 'Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.', 'Effect of natural mutations of SARS-CoV-2 on spike structure, conformation and antigenicity.', 'Chimeric spike mRNA vaccines protect against Sarbecoviru', 'Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein.', 'Interferon system deficiencies exacerbating severe pandemic virus infections.', 'The antigenic anatomy of SARS-CoV-2 receptor binding domain.', 'Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.', 'Targeting Fc effector function in vaccine design.', 'A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques.', 'SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19.', 'A homogeneous split-luciferase assay for rapid and sensitive detection of anti-SARS CoV-2 antibodies.', 'Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay.', 'DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice.', 'Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.', 'Association of Age With SARS-CoV-2 Antibody Response.', 'Long-term persistence of RBD', 'Rapid and reliable hybridoma screening method that is suitable for production of functional structure-recognizing monoclonal antibody.', 'Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.', 'Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.', 'Sustained neutralising antibodies in the Wuhan population suggest durable protection against SARS-CoV-2.', 'Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults.', 'Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.', 'Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease.', 'Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates.', 'Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination.', 'SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.', 'COVID-19 and ABO blood groups.', 'Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma.', 'A trend of dropping anti-SARS-CoV-2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors.', 'Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.', 'Computational Mutagenesis at the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Binding Interface: Comparison with Experimental Evidence.', 'A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.', 'Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice.', 'Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies.', 'A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies.', 'Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.', 'Antibody Dynamics, Seroreversion, and Persistence After SARS-CoV-2: Another Answer.', 'Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies.', 'Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.', 'Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches.', 'Development of multi-epitope peptide-based vaccines against SARS-CoV-2.', 'A brief review on potential application of mesenchymal stem cell and secretome in combating mortality and morbidity in COVID-19 patients.', 'Rapidly Increasing SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced from Plasma Collected During the 2020 Pandemic.', 'Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.', 'Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation.', 'SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals.', 'Antibody Response After SARS-CoV-2 Infection and Implications for Immunity : A Rapid Living Review.', 'A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2.', 'Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days.', 'The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization.', 'Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.', 'The conundrum of current anti-SARS-CoV-2 vaccines.', 'The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2.', 'The effect of spike mutations on SARS-CoV-2 neutralization.', 'Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients.', 'Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies.', 'SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.', 'A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.', 'Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.', 'Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India.', 'Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2.', 'SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.', 'Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.', 'Virus vaccines: proteins prefer prolines.', 'The great escape? SARS-CoV-2 variants evading neutralizing responses.', 'Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: Results of a community-based cohort.', 'Audio Interview: The Implications of Changes in the Structural Biology of SARS-CoV-2.', 'Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.', 'Experimental re-infected cats do not transmit SARS-CoV-2.', 'Shedding of Culturable Virus, Seroconversion, and 6-Month Follow-up Antibody Responses in the First 14 Confirmed Cases of Coronavirus Disease 2019 in the United States.', 'Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases.', 'Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2.', 'Serological Testing for COVID-19 Disease: Moving the Field of Serological Surveillance Forward.', 'Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma.', 'Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities.', 'Blockade of SARS-CoV-2 spike protein-mediated cell-cell fusion using COVID-19 convalescent plasma.', 'Susceptibility of white-tailed deer (', 'Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques Following SARS-CoV-2 Vaccination and Infection.', 'Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates.', 'Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks.', 'Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.', 'Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.', 'Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2.', 'Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19.', 'Donor Anti-Spike Immunity is Related to Recipient Recovery and Can Predict the Efficacy of Convalescent Plasma Units.', 'Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants.', 'Scalable, Micro-Neutralization Assay for Qualitative Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.', 'SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.', 'Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization.', 'Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates.', 'Neutralizing IFNL3 Autoantibodies in Severe COVID-19 Identified Using Molecular Indexing of Proteins by Self-Assembly.', 'Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice.', 'One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection.', 'A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike.', 'Phage Display Technique as a Tool for Diagnosis and Antibody Selection for Coronaviruses.', 'Process and operations strategies to enable global access to antibody therapies.', 'Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.', 'Neutralizing Activity of BNT162b2-Elicited Serum.', 'Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies.', 'Constraints and challenges in convalescent plasma collection amidst the Covid 19 pandemic- strategies and recommendations to overcome these.', 'Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area.', 'Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.', 'COVID-19 vaccines: modes of immune activation and future challenges.', 'Titers of Neutralizing Antibodies against SARS-CoV-2 Are Independent of Symptoms of Non-Severe COVID-19 in Young Adults.', 'Radioligand Assay-Based Detection of Antibodies against SARS-CoV-2 in Hospital Workers Treating Patients with Severe COVID-19 in Japan.', 'The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19.', 'Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library.', 'VOC 202012/01 Variant Is Effectively Neutralized by Antibodies Produced by Patients Infected before Its Diffusion in Italy.', 'Single-Molecule FRET Imaging of Virus Spike-Host Interactions.', 'Serological Response to SARS-CoV-2 in Health Care Workers Employed in a Large Tertiary Hospital in Lombardy, Northern Italy.', 'Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.', 'Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.', 'Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2.', 'Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.', 'Potential neutralizing antibodies discovered for novel corona virus using machine learning.', 'Development of SARS-CoV-2 vaccines.', 'COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges.', 'Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection.', 'Use of convalescent serum reduces severity of COVID-19 in nonhuman primates.', 'Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma.', 'Molecular and Cellular Biomarkers of COVID-19 Prognosis: Protocol for the Prospective Cohort TARGET Study.', 'Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques.', 'Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates.', 'Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain.', 'Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies.', \"A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2.\", 'Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.', 'Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients.', 'Emerging Technologies for the Treatment of COVID-19.', 'Immunodominant antibody germlines in COVID-19.', 'A Novel and Expanding SARS-CoV-2 Variant, B.1.526, Identified in New York.', 'Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant.', 'Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants.', 'Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies.', 'Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques.', \"'nAb' the self-reactive activity in the COVID-19 combat.\", 'Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model.', 'Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets.', 'Potential mechanisms of action of convalescent plasma in COVID-19.', 'Anti-A and SARS-CoV-2: an intriguing association.', 'Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters.', 'Previous viral symptoms and individual mothers influenced the leveled duration of human milk antibodies cross-reactive to S1 and S2 subunits from SARS-CoV-2, HCoV-229E, and HCoV-OC43.', 'S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates.', 'Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2.', 'SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages.', 'Seroconversion and Abundance of IgG Antibodies against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean Population.', 'Modalities and Mechanisms of Treatment for Coronavirus Disease 2019.', 'SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies.', 'Breadth and function of antibody response to acute SARS-CoV-2 infection in humans.', 'Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies.', 'Vaccine trials ramp up in children and adolescents.', 'Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers.', 'Prolonged SARS-CoV-2\\xa0cell culture replication in respiratory samples from patients with severe COVID-19.', 'A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs.', 'Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.', 'Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy.', 'Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.', 'SARS-CoV-2 in health and care staff in Norway, 2020.', 'Prolonged evolution of the human B cell response to SARS-CoV-2 infection.', 'Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.', 'Liver transplantation performed in a SARS-CoV-2 positive hospitalized recipient using a SARS-CoV-2 infected donor.', 'Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19.', 'SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.', 'Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2.', 'Convalescent plasma and hyperimmune globulin therapy in COVID-19.', 'Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.', 'SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys.', 'Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization.', 'Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV.', 'Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants.', 'Rotavirus as an Expression Platform of the SARS-CoV-2 Spike Protein.', 'A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.', 'COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.', 'Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients.', 'SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates.', 'Clinical, virologic and immunologic features of a mild case of SARS-CoV-2 reinfection.', 'Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.', 'Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors.', 'COVID-19: Diagnostics, Therapeutic Advances, and Vaccine Development.', 'Seroprevalence of neutralizing antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers in Makkah, Saudi Arabia.', 'Immunotherapy for COVID-19: Evolving treatment of viral infection and associated adverse immunological reactions.', 'Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19.', 'Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans.', 'Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil.', 'A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibody kinetics: Proposals for better quality of CCP collections.', 'Impaired Cellular Immunity to SARS-CoV-2 in Severe COVID-19 Patients.', 'The long road.', 'Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2.', 'Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion in hematology-oncology patients.', 'Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.', 'Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677.', 'Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates.', 'A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection.', 'SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies.', \"The coronavirus is here to stay - here's what that means.\", 'Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera.', 'Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies.', 'Persistence of SARS-CoV-2-specific B and T\\xa0cell responses in convalescent COVID-19 patients 6-8\\xa0months after the infection.', 'Antibody titers against SARS-CoV-2 decline, but do not disappear for several months.', 'Humoral signatures of protective and pathological SARS-CoV-2 infection in children.', 'Discrete SARS-CoV-2 antibody titers track with functional humoral stability.', 'Neutralizing monoclonal antibodies for COVID-19 treatment and prevention.', 'Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library.', 'Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China.', 'Quantitative assays reveal cell fusion at minimal levels of SARS-CoV-2 spike protein and fusion from without.', 'Safety and Efficacy of Convalescent Plasma in Elderly COVID-19 Patients: The RESCUE Trial.', 'Reinfection or Reactivation of Coronavirus-19 in Patients with Hematologic Malignancies: Case Report Series.', 'Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses.', 'Cytokine Signature Induced by SARS-CoV-2 Spike Protein in a Mouse Model.', 'Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals.', 'Treatment and control strategies for COVID-19: Prospects and possibilities.', 'Longitudinal analysis of antibody response following SARS-CoV-2 infection in pregnancy: From the first trimester to delivery.', 'Avidity assay to test functionality of anti-SARS-Cov-2 antibodies.', \"How 'killer' T cells could boost COVID immunity in face of new variants.\", 'Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice.', 'Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques.', 'Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile.', 'Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2\\xa0S for viral entry.', 'Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection.', 'Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand.', 'High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.', 'Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan.', 'Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody.', 'SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters.', 'Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization.', 'Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.', 'Immune response scenario and vaccine development for SARS-CoV-2 infection.', 'Maturation and persistence of the anti-SARS-CoV-2 memory B cell response.', 'Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors.', 'In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses.', 'Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality.', 'Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.', 'Durable SARS-CoV-2 B cell immunity after mild or severe disease.', 'Current treatment in COVID-19 disease: a rapid review.', 'Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature.', 'In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.', 'mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.', 'The challenge of avidity determination in SARS-CoV-2 serology.', 'TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability.', 'Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant.', 'Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals.', 'Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike.', 'Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination.', 'Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia.', 'Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection.', 'Characterization of SARS-CoV-2 RNA, Antibodies, and Neutralizing Capacity in Milk Produced by Women with COVID-19.', 'Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity.', 'HIV mRNA Vaccines-Progress and Future Paths.', 'Localized and Systemic Immune Responses against SARS-CoV-2 Following Mucosal Immunization.', 'Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection.', 'Variant-proof vaccines - invest now for the next pandemic.', 'Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.', 'Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers.', 'The G614 pandemic SARS-CoV-2 variant is not more pathogenic than the original D614 form in adult Syrian hamsters.', 'A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques.', 'Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay.', 'Stable neutralizing antibody levels 6\\xa0months after mild and severe COVID-19 episodes.', 'Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma.', 'Development of a Fast SARS-CoV-2 IgG ELISA, Based on Receptor-Binding Domain, and Its Comparative Evaluation Using Temporally Segregated Samples From RT-PCR Positive Individuals.', 'A serological survey of severe acute respiratory syndrome coronavirus 2 in dogs in Wuhan.', 'How glycobiology can help us treat and beat the COVID-19 pandemic.', 'Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.', 'Evidence of early circulation of SARS-CoV-2 in France: findings from the population-based \"CONSTANCES\" cohort.', 'A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.', 'SARS-CoV-2 evolution during treatment of chronic infection.', 'Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.', 'DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice.', 'A Neutralization Assay Based on Pseudo-Typed Lentivirus with SARS CoV-2 Spike Protein in ACE2-Expressing CRFK Cells.', 'A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.', 'Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape.', 'Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.', 'Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.', 'Monoclonal Antibody for Patients with Covid-19. Reply.', 'Monoclonal Antibody for Patients with Covid-19.', 'Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting.', 'Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers.', 'The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.', 'SARS-CoV-2 recruits a haem metabolite to evade antibody immunity.', 'Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques.', 'Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain.', 'mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge.', 'Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset.', 'A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques.', 'Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail.', 'Development of spike receptor-binding domain nanoparticle as a vaccine candidate against SARS-CoV-2 infection in ferrets.', 'SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines.', 'Does COVID-19 antibody serology testing correlate with disease severity? An analytical descriptive retrospective study.', 'SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses.', 'Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2.', 'SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.', 'A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice.', 'Virological Characterization of the First 2 COVID-19 Patients Diagnosed in Italy: Phylogenetic Analysis, Virus Shedding Profile From Different Body Sites, and Antibody Response Kinetics.', 'Isolation of SARS-CoV-2 strains carrying a nucleotide mutation, leading to a stop codon in the ORF 6 protein.', 'BNT162b vaccines protect rhesus macaques from SARS-CoV-2.', 'What do we know about the antibody responses to SARS-CoV-2?', 'COVID-19 convalescent plasma composition and immunological effects in severe patients.', 'Potent mouse monoclonal antibodies that block SARS-CoV-2 infection.', 'Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.', 'Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.', 'A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice.', 'Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.', 'Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model.', 'Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral Entry and Neutralization Assays: A 1-Week Protocol.', 'Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection.', 'The Utility of Specific Antibodies Against SARS-CoV-2 in Laboratory Diagnosis.', 'COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review.', 'Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.', 'Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients.', 'Absence of Vaccine-enhanced Disease With Unexpected Positive Protection Against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Inactivated Vaccine Given Within 3 Days of Virus Challenge in Syrian Hamster Model.', 'SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus.', 'Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA.', 'Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.', 'Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.', 'Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants.', 'Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia.', 'Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: A cross-sectional study.', 'Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review.', 'SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity.', 'Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in\\xa0the 6 months following SARS-CoV-2 infection.', 'Longitudinal SARS-CoV-2 seroconversion and functional heterogeneity in a pediatric dialysis unit.', 'Switched and unswitched memory B cells detected during SARS-CoV-2 convalescence correlate with limited symptom duration.', 'Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-COV-2 Individuals.', 'The immunodominant and neutralization linear epitopes for SARS-CoV-2.', 'mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.', 'Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine.', 'Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.', 'mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.', 'Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease.', 'Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine.', 'Antibodies, epicenter of SARS-CoV-2 immunology.', 'A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection.', 'Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.', 'A 10-Minute \"Mix and Read\" Antibody Assay for SARS-CoV-2.', 'Adaptive immunity to SARS-CoV-2 and COVID-19.', 'Audio Interview: Covid-19 in South Africa and a New SARS-CoV-2 Variant.', 'Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study.', 'Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam.', 'Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses.', 'Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters.', 'Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.', 'Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate.', 'Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses.', 'Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis.', 'ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population.', 'A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy.', 'Broad-Spectrum Antiviral Agents Based on Multivalent Inhibitors of Viral Infectivity.', 'Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing.', 'SARS-CoV-2 Viral RNA Shedding for More Than 87 Days in an Individual With an Impaired CD8+ T Cell Response.', 'Bioinformatics prediction of B and T cell epitopes within the spike and nucleocapsid proteins of SARS-CoV2.', 'Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.', 'Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD.', 'A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.', 'Antibody persistence in the first 6\\xa0months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study.', 'Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany.', 'Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered ', 'Fast-spreading COVID variant can elude immune responses.', 'SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness.', 'Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.', 'Prophylaxis for COVID-19: a systematic review.', 'Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19.', 'Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC.', 'Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19.', 'Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.', 'Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape.', 'Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial.', 'Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection.', 'Flow cytometry multiplexed method for the detection of neutralizing human antibodies to the native SARS-CoV-2 spike protein.', 'N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.', 'CAR-NK Cells Effectively Target the D614 and G614 SARS-CoV-2-infected Cells.', 'SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike.', 'Intranasal Infection of Ferrets with SARS-CoV-2 as a Model for Asymptomatic Human Infection.', 'Mapping and role of T cell response in SARS-CoV-2-infected mice.', 'Evolution of antibody immunity to SARS-CoV-2.', 'Disease-duration based comparison of subsets of immune cells in SARS CoV-2 infected patients presenting with mild or severe symptoms identifies prognostic markers for severity.', 'Presence and short-term persistence of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent plasma donors.', 'Development of Coronavirus Treatments Using Neutralizing Antibodies.', 'Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan.', 'Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays.', 'Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial.', 'SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.', 'Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset.', 'Age is not a disease: Evolution of protective antibodies against SARS-CoV-2 in seniors from the B&#345;evnice nursing home.', 'Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina.', 'Self-organized stem cell-derived human lung buds with proximo-distal patterning and novel targets of SARS-CoV-2.', 'The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates.', 'MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease.', 'Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.', 'Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates.', 'A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques.', 'Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection.', 'SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines.', 'Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.', 'A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.', 'Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.', 'Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.', 'Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.', 'Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.', 'Comparison of the SARS-CoV-2 (2019-nCoV) M protein with its counterparts of SARS-CoV and MERS-CoV species.', 'Could new COVID variants undermine vaccines? Labs scramble to find out.', 'Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19).', 'Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.', 'Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry.', 'Generation and Characterization of recombinant SARS-CoV-2 expressing reporter genes.', 'Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections.', 'SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals.', 'Antibody response to SARS-CoV-2 in infected patients with different clinical outcome.', 'Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022.', 'Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice.', 'Recombinant protein vaccines, a proven approach against coronavirus pandemics.', 'Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2.', 'Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma.', 'Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins.', 'COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.', 'Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques.', 'Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies.', 'COVID-19-neutralizing antibodies predict disease severity and survival.', 'Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer.', 'Living with respiratory viruses: The next saga in human/viral coexistence?', 'A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity.', 'Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.', 'Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission.', 'SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia.', 'Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays.', 'Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review: 31.', 'Evaluation of High-Throughput SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-19: Clinical Sensitivity, Specificity, and Association with Virus Neutralization Test.', 'Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates.', 'A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques.', 'MHC-II constrains the natural neutralizing antibody response to the SARS-CoV-2 spike RBM in humans.', 'SARS-CoV-2 escape ', 'Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection.', 'Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations.', 'Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma.', 'SARS-CoV-2 structural features may explain limited neutralizing-antibody responses.', 'Neutralizing antibody titres in SARS-CoV-2 infections.', 'Stereotypic neutralizing V', 'Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions.', 'Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval.', 'Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.', 'CRISPR-based strategies in infectious disease diagnosis and therapy.', 'Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.', 'A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters.', 'Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents.', 'Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).', 'Differential serological and neutralizing antibody dynamics after an infection by a single SARS-CoV-2 strain.', 'Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures.', 'Audio Interview: A Look at Covid-19 Prevention and Care in 2020.', 'Antibody response to SARS-CoV-2 infection in humans: A systematic review.', 'Design of a companion bioinformatic tool to detect the emergence and geographical distribution of SARS-CoV-2 Spike protein genetic variants.', 'Comparison of Four SARS-CoV-2 Neutralization Assays.', 'Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply.', 'Neutralizing Antibody LY-CoV555 for Outpatient Covid-19.', 'The development of neutralizing antibodies against SARS-CoV-2 and their common features.', 'The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.', 'Do Animals Play a Role in the Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)? A Commentary.', 'SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution.', 'Harnessing Cellular Immunity for Vaccination against Respiratory Viruses.', 'Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2.', 'Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting.', 'SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing.', 'Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020).', 'Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates.', 'Biological Significance of Anti-SARS-CoV-2 Antibodies: Lessons Learned From Progressive Multifocal Leukoencephalopathy.', 'Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection.', 'High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms.', 'COVID-19 vaccines: The status and perspectives in delivery points of view.', 'Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.', 'Nanobodies, the potent agents to detect and treat the Coronavirus infections: A systematic review.', 'Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2.', 'Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.', 'Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?', 'Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality.', 'High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme.', 'Susceptibility of Domestic Swine to Experimental Infection with Severe Acute Respiratory Syndrome Coronavirus 2.', 'Viral infection neutralization tests: A focus on severe acute respiratory syndrome-coronavirus-2 with implications for convalescent plasma therapy.', 'SARS-CoV-2 infection in farmed minks, associated zoonotic concerns, and importance of the One Health approach during the ongoing COVID-19 pandemic.', 'Occurrence of Antibodies against SARS-CoV-2 in the Domestic Cat Population of Germany.', 'A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine.', 'Microfluidic immunoassay for detection of serological antibodies: A potential tool for rapid evaluation of immunity against SARS-CoV-2.', 'Neutralizing antibodies targeting SARS-CoV-2 spike protein.', 'Persistence of IgG response to SARS-CoV-2.', 'Possible treatment and strategies for COVID-19: review and assessment.', 'T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.', 'Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.', 'Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.', 'REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.', 'Understanding the outcomes of COVID-19 - does the current model of an acute respiratory infection really fit?', 'Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trials.', 'Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motif.', 'Natural SARS-CoV-2 infections, including virus isolation, among serially tested cats and dogs in households with confirmed human COVID-19 cases in Texas, USA.', 'Mild SARS-CoV-2 Infection After Gene Therapy in a Child With Wiskott-Aldrich Syndrome: A Case Report.', 'Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors.', 'Serologic Evaluation of Healthcare Workers Caring for COVID-19 Patients in the Republic of Korea.', 'A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.', 'How COVID-19 is changing the cold and flu season.', 'Picomolar SARS-CoV-2 Neutralization Using Multi-Arm PEG Nanobody Constructs.', 'SARS-CoV-2 infections among healthcare workers at Helsinki University Hospital, Finland, spring 2020: Serosurvey, symptoms and risk factors.', 'Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.', 'Neutralizing SARS-CoV-2.', 'Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.', '6-month SARS-CoV-2 antibody persistency in a\\xa0Tyrolian COVID-19 cohort.', 'Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection of a Healthcare Worker in a Belgian Nosocomial Outbreak Despite Primary Neutralizing Antibody Response.', 'Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies.', 'Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection.', 'Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in Pichia pastoris and mammalian cells.', 'The kinetics of humoral response and its relationship with the disease severity in COVID-19.', 'Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects.', 'The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition.', 'Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.', 'Multicenter Evaluation of the Clinical Performance and the Neutralizing Antibody Activity Prediction Properties of 10 High-Throughput Serological Assays Used in Clinical Laboratories.', 'Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2.', 'COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus.', 'A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.', 'Long-term SARS-CoV-2 RNA shedding and its temporal association to IgG seropositivity.', 'Production and use of convalescent plasma in COVID-19 treatment, taking into account the experience in the Central Millitary Hospital Prague.', 'Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals.', 'Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.', 'SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation.', 'Neutralizing antibodies for the treatment of COVID-19.', 'Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients.', 'Interferon linked to COVID-19 severity.', 'Baculovirus-free insect cell expression system for high yield antibody and antigen production.', 'IgA dominates the early neutralizing antibody response to SARS-CoV-2.', 'Enhanced SARS-CoV-2 neutralization by dimeric IgA.', 'Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome.', 'A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol.', 'Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity.', 'A Prospective Study on Rapidly Declining SARS-CoV-2 IgG Antibodies Within One to Three Months of Testing IgG Positive: Can It Lead to Potential Reinfections?', 'Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes.', 'Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy.', 'B careful: Humoral responses and COVID-19 severity.', 'Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19.', 'Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma.', 'Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.', 'A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody.', 'Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains.', 'Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward.', 'Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.', 'Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection.', 'A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry ', 'A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2.', 'Identification of HLA-A*02:01-restricted candidate epitopes derived from the non-structural polyprotein 1a of SARS-CoV-2 that may be natural targets of CD8', 'Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity.', 'Structure-based development of human antibody cocktails against SARS-CoV-2.', 'Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection.', 'The immunology of SARS-CoV-2 infections and vaccines.', 'Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.', 'Serological Surveillance of COVID-19 Hospitalized Patients in Réunion Island (France) Revealed that Specific Immunoglobulin G Are Rapidly Vanishing in Severe Cases.', 'Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study.', 'A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.', 'Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition.', 'High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.', 'Detection of breastmilk antibodies targeting SARS-CoV-2 nucleocapsid, spike and receptor-binding-domain antigens.', 'Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform.', 'A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine.', 'Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial.', 'Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control.', 'Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.', 'Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Reactive Antibodies: December 2019-January 2020.', 'Nanomedicinal delivery of stimulator of\\xa0interferon genes agonists: recent advances in virus vaccination.', 'Why METH users are at high risk of fatality due to COVID-19 infection?', 'SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.', 'RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.', 'An unusual COVID-19 case with over four months of viral shedding in the presence of low neutralizing antibodies: a case report.', 'Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity.', 'Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models.', 'Single cell RNA and immune repertoire profiling of COVID-19 patients reveal novel neutralizing antibody.', 'Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS-CoV-2 neutralizing activity of sera.', 'Dysregulated immunity in SARS-CoV-2 infected pregnant women.', 'Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients.', 'Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.', 'Virology, epidemiology, immunology and vaccine development of SARS-CoV-2, update after nine months of pandemic.', 'Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate.', 'Non-neutralizing antibodies and limitations of serologic testing for severe acute respiratory syndrome coronavirus 2 in patients receiving immunoglobulin replacement products.', 'A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.', 'Biodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study.', 'Recombinant vaccines for COVID-19.', 'Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidate.', 'Antibodies, Immunity, and COVID-19.', 'COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research.', 'Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine.', 'Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay.', 'A Strategy to Battle Coronavirus Disease 2019 in the Hospital: Identify and Use the Power of \"Immune Survivors\".', 'Letter to the editor: Neutralizing antibodies for the treatment of COVID-19.', 'Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19.', 'Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19.', 'Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.', 'Coinfection by Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza A(H1N1)pdm09 Virus Enhances the Severity of Pneumonia in Golden Syrian Hamsters.', 'Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies.', 'COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19.', 'What the data say about asymptomatic COVID infections.', 'Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.', 'Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19.', 'SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals.', 'How should we use convalescent plasma therapies for the management of COVID-19?', 'Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.', 'Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2.', 'Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization.', 'Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals.', 'Prolonged shedding of severe acute respiratory syndrome coronavirus 2 in patients with COVID-19.', 'ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives.', 'CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization.', 'Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals.', 'Seroprevalence of SARS-CoV-2 infection among pet animals in Croatia and potential public health impact.', 'Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2.', 'Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.', 'Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity.', 'Spike Glycoprotein-Mediated Entry of SARS Coronaviruses.', 'Structural basis of severe acute respiratory syndrome coronavirus 2 infection.', 'Adaptation of advanced clinical virology assays from HIV-1 to SARS-CoV-2.', 'Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020.', 'COVID-19: Way Forward With Serosurveillance Without Overemphasizing Neutralizing Antibodies.', 'Immunological Assessment of Pediatric Multisystem Inflammatory Syndrome Related to Coronavirus Disease 2019.', 'COVID-19 in the Developing World: Is the Immune Response to α-Gal an Overlooked Factor Mitigating the Severity of Infection?', 'N-Acetylcysteine to Combat COVID-19: An Evidence Review.', 'Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19.', 'Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.', 'Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2.', 'Evolution of Antibody Immunity to SARS-CoV-2.', 'SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice.', 'The PentaFOLD 3.0 Algorithm for the Selection of Stable Elements of Secondary Structure to be Included in Vaccine Peptides.', 'Why will it never be known if convalescent plasma is effective for COVID-19.', 'SARS-CoV-2 and interferon blockade.', 'Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020.', 'Antibody-Based Immunotherapeutic Strategies for COVID-19.', 'Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases.', 'Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults.', 'A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.', 'A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds.', 'Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview.', 'COVID-19 update: The race to therapeutic development.', 'Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.', 'Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity.', 'Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.', 'Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation.', 'Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG.', 'Long-Term Existence of SARS-CoV-2 in COVID-19 Patients: Host Immunity, Viral Virulence, and Transmissibility.', 'Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum.', 'Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein.', 'Convalescent plasma - Is it useful for treating SARS Co-V2 infection?', 'Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment.', 'Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2.', 'An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike.', 'COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response.', 'Isolation and characterization of an early SARS-CoV-2 isolate from the 2020 epidemic in Medellín, Colombia', 'Viral RNA level, serum antibody responses, and transmission risk in recovered COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study.', 'Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.', 'SARS-CoV-2 Cysteine-like Protease Antibodies Can Be Detected in Serum and Saliva of COVID-19-Seropositive Individuals.', '', 'Intra-host non-synonymous diversity at a neutralizing antibody epitope of SARS-CoV-2 spike protein N-terminal domain.', 'Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients.', 'Durable SARS-CoV-2 B cell immunity after mild or severe disease.', 'A cell-free antibody engineering platform rapidly generates SARS-CoV-2 neutralizing antibodies.', 'Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods.', 'A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization.', 'Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera.', 'Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers.', 'NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge.', 'Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping.', 'Virological and Serological Discordant Profiles in COVID-19 Pneumonia: Two Atypical Clinical Cases.', 'Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.', 'Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.', 'Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area.', 'Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.', 'Kawasaki-like disease and acute myocarditis in the SARS-CoV-2 pandemic - reports of three adolescents.', 'A SARS-CoV-2 variant with the 12-bp deletion at E gene.', 'An Effective COVID-19 Vaccine Needs to Engage T Cells.', 'The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens.', 'Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.', 'Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization.', 'SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.', 'COVID-19, varying genetic resistance to viral disease and immune tolerance checkpoints.', 'Common childhood vaccines do not elicit a cross-reactive antibody response against SARS-CoV-2.', 'Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.', 'SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination.', 'Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.', 'COVID-19 neutralizing antibodies predict disease severity and survival.', 'Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.', 'Spike mutation D614G alters SARS-CoV-2 fitness.', 'Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.', 'Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study.', 'The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.', 'Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.', 'Neutralizing Antibody Responses in COVID-19 Convalescent Sera.', 'Change of Antigenic Determinants of SARS-CoV-2 Virus S-Protein as a Possible Cause of Antibody-Dependent Enhancement of Virus Infection and Cytokine Storm.', 'An Overview of the Crystallized Structures of the SARS-CoV-2.', 'Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological Immunoassay.', 'A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone.', 'The Interaction of Natural and Vaccine-Induced Immunity with Social Distancing Predicts the Evolution of the COVID-19 Pandemic.', 'Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response.', 'Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19.', 'Vaccines against COVID-19.', 'SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020.', 'Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020.', 'Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.', 'Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).', 'Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.', 'Serologic Responses in Healthy Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020.', 'Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2.', \"Nature's second pandemic progress report.\", 'The bumpy road to achieve herd immunity in COVID-19.', 'Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders.', 'Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2.', 'Deep mutagenesis in the study of COVID-19: a technical overview for the proteomics community.', 'Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset.', 'Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.', 'Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.', 'Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate.', 'Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.', 'Identification and Tracking of Antiviral Drug Combinations.', 'R2N and the use of alternative methods in COVID-19 research.', 'Pathogenesis-directed therapy of 2019 novel coronavirus disease.', 'Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment.', 'Type I IFN-dependent antibody response at the basis of sex dimorphism in the outcome of COVID-19.', 'Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies.', 'Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.', 'Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.', 'Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals.', 'Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection.', 'A patient infected with SARS-CoV-2 over 100 days.', 'Evaluation of 3 SARS-CoV-2 IgG Antibody Assays and Correlation with Neutralizing Antibodies.', 'SARS-CoV-2-specific antibody rearrangements in prepandemic immune repertoires of risk cohorts and patients with COVID-19.', 'Review of COVID-19 Antibody Therapies.', 'Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects.', 'A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.', 'A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.', 'Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell-cell fusion.', 'Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.', 'Clinical, laboratory, and temporal predictors of neutralizing antibodies to SARS-CoV-2 after COVID-19.', 'SARS-CoV-2-specific peripheral T follicular helper cells correlate with neutralizing antibodies and increase during convalescence.', 'Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice.', 'CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiation.', 'Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors.', 'Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection.', 'SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.', 'Validation and clinical evaluation of a SARS-CoV-2\\u2005surrogate virus neutralisation test (sVNT).', 'Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective.', 'Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions.', 'Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections.', 'Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.', 'REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.', 'Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals.', 'Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors.', 'Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.', 'Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses.', 'Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.', '', 'Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.', 'Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19.', 'SARS-CoV-2 infection, disease and transmission in domestic cats.', 'An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain.', 'An approach to lifting self-isolation for health care workers with prolonged shedding of SARS-CoV-2 RNA.', 'Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area.', 'SARS-CoV-2 D614G Variant Exhibits Enhanced Replication ', 'LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.', 'A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters.', 'Do cross-reactive antibodies cause neuropathology in COVID-19?', 'The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series.', 'Application, Verification, and Implementation of SARS-CoV-2 Serologic Assays with Emergency Use Authorization.', 'Confidence intervals for the COVID-19 neutralizing antibody retention rate in the Korean population.', 'Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection.', 'Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike.', 'Characterization of local SARS-CoV-2 isolates and pathogenicity in IFNAR', 'Evaluation of Neutralizing Antibodies Against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus Pseudovirus-Based Assay.', 'Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.', 'Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.', 'Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development.', 'Treatment of coronavirus disease 2019.', 'SARS-CoV-2 infection serology validation of different methods: Usefulness of IgA in the early phase of infection.', 'Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset.', 'COVID-19 vaccine BNT162b1 elicits human antibody and T', 'Accuracy of serological testing for SARS-CoV-2 antibodies: First results of a large mixed-method evaluation study.', 'COVID-19 and human milk: SARS-CoV-2, antibodies, and neutralizing capacity.', 'AI-guided discovery of the invariant host response to viral pandemics.', 'A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody.', 'Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model.', 'Neutralization Assay with SARS-CoV-1 and SARS-CoV-2 Spike Pseudotyped Murine Leukemia Virions.', 'Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates.', 'Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection.', 'Distinct B cell subsets give rise to antigen-specific antibody responses against SARS-CoV-2.', 'Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity.', 'Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats.', 'Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.', 'Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.', 'Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.', 'Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain.', 'Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays.', 'The Antibody Response to SARS-CoV-2 Infection.', 'Effectiveness of personal protective equipment in preventing severe acute respiratory syndrome coronavirus 2 infection among healthcare workers.', 'COVID-19: Significance of antibodies.', 'The Rapid Coronavirus Antibody Test: Can We Improve Accuracy?', 'What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist.', 'The complexities of SARS-CoV-2 serology.', 'Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations.', 'Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay.', 'Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19.', 'COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2.', 'The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.', 'Flawed interferon response spurs severe illness.', 'Autoantibodies against type I IFNs in patients with life-threatening COVID-19.', 'Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.', 'Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.', 'Serum Antibody Profile of a Patient With Coronavirus Disease 2019 Reinfection.', 'Immune response following infection with SARS-CoV-2 and other coronaviruses: A rapid review.', 'Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.', 'Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).', 'Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients.', 'Carbohydrate-Binding Agents: Potential of Repurposing for COVID-19 Therapy.', 'Efficacy of convalescent plasma according to blood groups in COVID-19 patients', 'Antibody-like proteins that capture and neutralize SARS-CoV-2.', 'Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.', 'SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.', 'Impact of Circulating SARS-CoV-2 Mutant G614 on the COVID-19 Pandemic.', 'Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control.', 'High Potency of a Bivalent Human V', 'Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2.', 'No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic.', 'Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.', 'Acetylated K676 TGFBIp as a severity diagnostic blood biomarker for SARS-CoV-2 pneumonia.', 'Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.', 'SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with nonsevere disease.', '[Immunity against SARS-CoV-2: walking to the vaccination].', 'Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition.', 'Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro.', 'Antibody binding to SARS-CoV-2 S glycoprotein correlates with, but does not predict neutralization.', 'Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?', 'Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma.', 'A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2.', 'Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles.', 'SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease.', 'Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition.', 'Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays.', 'A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19.', 'Update on newer approaches to prevent or treat COVID-19 infection: What we all need the most right now!!', 'Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.', 'COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease.', 'COVID-19 and the Path to Immunity.', 'A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients.', 'Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.', 'Snatching the Crown from SARS-CoV-2.', 'Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization.', 'SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.', 'Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers.', 'Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.', 'Interim analysis of the clinical performance of five SARS-Cov-2 serology assays.', 'Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement.', 'Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2-Infected Syrian Hamsters.', 'Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins.', 'Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice.', 'The kinetics of viral load and antibodies to SARS-CoV-2.', 'SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.', 'Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.', 'Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients.', 'Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.', 'Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells.', 'Oromucosal immunomodulation as clinical spectrum mitigating factor in SARS-CoV-2 infection.', 'Kinetics of Viral Clearance and Antibody Production Across Age Groups in Children with Severe Acute Respiratory Syndrome Coronavirus 2 Infection.', 'CoV3D: a database of high resolution coronavirus protein structures.', 'An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.', \"Antibody Responses to SARS-CoV-2: Let's Stick to Known Knowns.\", 'Overcoming Symmetry Mismatch in Vaccine Nanoassembly through Spontaneous Amidation.', 'Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome.', 'Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters.', 'SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients.', 'Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19.', 'Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).', 'Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.', 'Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication.', 'Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.', 'What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?', 'Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk.', 'A simple protein-based surrogate neutralization assay for SARS-CoV-2.', 'Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2.', 'A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice.', 'Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies.', 'A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants.', 'A serological survey of SARS-CoV-2 in cat in Wuhan.', 'Testing for responses to the wrong SARS-CoV-2 antigen?', 'Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test ', 'Age-Related Differences in Immunological Responses to SARS-CoV-2.', 'Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients.', 'Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia.', 'A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.', 'SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients.', 'Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR.', 'Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion.', 'Functional Pangenome Analysis Shows Key Features of E Protein Are Preserved in SARS and SARS-CoV-2.', 'Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung.', 'Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.', 'SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig.', 'Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19.', 'Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Angiotensin Converting Enzyme 2 Binding and Endocytosis.', 'Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population.', 'Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding.', 'The Disillusioned Comfort with COVID-19 and the Potential of Convalescent Plasma and Cell Therapy.', 'Antibody Responses and Clinical Outcomes in Adults Hospitalized With Severe Coronavirus Disease 2019 (COVID-19): A Post hoc Analysis of LOTUS China Trial.', 'Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2.', 'Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.', 'Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.', 'Live unattenuated vaccines for controlling viral diseases, including COVID-19.', 'Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2.', 'A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.', 'An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques.', 'A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.', 'Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate.', 'SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients.', 'Evidence lags behind excitement over blood plasma as a coronavirus treatment.', 'Clinical performances of an ELISA for SARS-CoV-2 antibody assay and correlation with neutralization activity.', 'Functional SARS-CoV-2-specific immune memory persists after mild COVID-19.', 'Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate.', 'Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure.', 'Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera.', 'Functional SARS-CoV-2-specific immune memory persists after mild COVID-19.', 'A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model.', 'Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells.', 'Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2.', 'Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice.', 'Antibody response in a family with COVID-19.', 'Genome-wide analysis of SARS-CoV-2 virus strains circulating worldwide implicates\\xa0heterogeneity.', 'What the immune response to the coronavirus says about the prospects for a vaccine.', 'Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China.', 'Neutralizing Antibodies Against SARS-CoV-2-Important Questions, Unclear Answers.', 'Structures and distributions of SARS-CoV-2 spike proteins on intact virions.', 'CoV-AbDab: the coronavirus antibody database.', 'A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy.', 'Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice.', 'Anti-SARS-CoV-2 spike antibodies are stable in convalescent plasma when stored at 4° Celsius for at least 6\\u2009weeks.', 'Plasma From Recovered COVID-19 Patients Inhibits Spike Protein Binding to ACE2 in a Microsphere-Based Inhibition Assay.', 'Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.', 'False-positive SARS-CoV-2 serology in 3 children with Kawasaki disease.', 'A Thermostable mRNA Vaccine against COVID-19.', 'A practical approach for the compassionate use of convalescent plasma in patients with severe COVID-19 in developing countries.', 'Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay.', 'Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals.', 'Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity.', 'Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate.', 'A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.', 'Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.', 'Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.', 'Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.', 'Phase\\xa0I/II study of COVID-19 RNA vaccine BNT162b1 in adults.', 'A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.', 'Antibody therapies could be a bridge to a coronavirus vaccine - but will the world benefit?', \"Russia's fast-track coronavirus vaccine draws outrage over safety.\", 'The role of IgG Fc receptors in antibody-dependent enhancement.', 'Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.', 'Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.', 'Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19.', 'Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.', 'Clinical Utility of a Highly Sensitive Lateral Flow Immunoassay as determined by Titer Analysis for the Detection of anti-SARS-CoV-2 Antibodies at the Point-of-Care.', 'Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.', 'A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine.', 'Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.', 'COVID-19 in Africa: Dampening the storm?', 'Why do children seem to be more protected against COVID-19? A hypothesis.', 'High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects.', 'Fast-and-fit vaccines.', 'A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2.', 'SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.', 'Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation.', 'Naturally occurring SARS-CoV-2 gene deletions close to the spike S1/S2 cleavage site in the viral quasispecies of COVID19 patients.', 'Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France.', 'Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.', 'Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects.', 'Dynamics and significance of the antibody response to SARS-CoV-2 infection.', 'Kinetics and Isotype Assessment of Antibodies Targeting the Spike Protein Receptor Binding Domain of SARS-CoV-2 In COVID-19 Patients as a function of Age and Biological Sex.', 'Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy.', 'The SARS-CoV-2 Spike Variant D614G Favors an Open Conformational State.', 'An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain.', 'Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.', 'Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate.', 'Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with an endemic human CoV.', 'Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2.', 'An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection.', 'A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.', 'Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases.', 'Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.', 'Cellular immune responses to covid-19.', 'Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.', 'Letter to the editor: COVID-19: how accurate are seroprevalence studies?', 'Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.', 'The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.', 'SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital.', 'A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.', 'Developing a low-cost and accessible COVID-19 vaccine for global health.', 'Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.', 'Perspectives for immune plasma treatment of COVID-19', 'Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.', \"Coronavirus vaccines leap through safety trials - but which will work is anybody's guess.\", 'Neutralizing Antibody Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 Patients.', 'COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis.', 'COVID-19: Mechanisms of Vaccination and Immunity.', 'Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections.', 'A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction.', 'Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.', 'Promise and challenges in the development of COVID-19 vaccines.', 'Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.', 'Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.', 'Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.', 'Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020.', 'Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19.', 'Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization.', 'Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.', 'Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development.', 'Coronavirus vaccines get a biotech boost.', 'Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.', 'SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.', 'An ', 'An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.', 'SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection.', 'Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes.', 'Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test.', 'Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors.', 'Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development.', 'Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19.', 'Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.', 'COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.', 'Potently neutralizing and protective human antibodies against SARS-CoV-2.', 'Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.', 'An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.', 'An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein.', 'COVID-19 Antibody Trials Have Begun.', 'Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.', 'Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19.', 'Structural basis of a shared antibody response to SARS-CoV-2.', 'A perspective on potential antibody-dependent enhancement of SARS-CoV-2.', \"Immunoglobulin fragment F(ab')\", 'Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2.', 'Disappearance of antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery.', 'Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays.', 'Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.', 'Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.', 'Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks.', 'Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.', 'Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics?', 'A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.', 'Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.', 'Thinking more about therapy with convalescent plasma for COVID-19 patients.', 'SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.', 'Using iCn3D and the World Wide Web for structure-based collaborative research: Analyzing molecular interactions at the root of COVID-19.', 'Glycans on the SARS-CoV-2 Spike Control the Receptor Binding Domain Conformation.', 'Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine.', 'A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies.', 'Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques.', 'Kinetics of viral load and antibody response in relation to COVID-19 severity.', 'SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy.', 'The \"scar\" of a pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy.', 'An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment.', 'Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?', 'Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles.', 'Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.', 'Going back in time for an antibody to fight COVID-19.', 'Longitudinal anti-SARS-CoV-2 antibody profile and neutralization activity of a COVID-19 patient.', 'Six months of coronavirus: the mysteries scientists are still racing to solve.', 'High neutralizing antibody titer in intensive care unit patients with COVID-19.', 'Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.', 'Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.', 'Mining of epitopes on spike protein of SARS-CoV-2 from COVID-19 patients.', 'Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development.', 'Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?', 'Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.', 'A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.', 'SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected, hospitalized COVID-19 patients.', \"Coronaviruses' sugar shields as vaccine candidates.\", 'SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets.', 'Sex and gender differences in the outcome of patients with COVID-19.', 'Antibody responses against SARS-CoV-2 in COVID-19 patients.', 'Review of COVID-19 Antibody Therapies.', 'Coronavirus vaccine-associated lung immunopathology-what is the significance?', 'SARS-CoV-2 neutralizing antibody development strategies.', 'COVID-19 Vaccines: \"Warp Speed\" Needs Mind Melds, Not Warped Minds.', 'A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.', 'Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19.', 'Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike.', 'Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding.', 'Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.', 'Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.', 'Review of Current Advances in Serologic Testing for COVID-19.', 'Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020.', 'Does Early Childhood Vaccination Protect Against COVID-19?', 'Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS.', 'Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively.', 'Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients.', 'In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies.', 'Detection of SARS-CoV-2 neutralizing antibodies with a cell-free PCR assay.', 'Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients.', 'Long-term SARS-CoV-2 RNA Shedding and its Temporal Association to IgG Seropositivity.', 'Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 ', 'Closing coronavirus spike glycoproteins by structure-guided design.', 'Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.', 'CoV3D: A database and resource for high resolution coronavirus protein structures.', 'Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2.', 'Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies.', 'Structural basis of a public antibody response to SARS-CoV-2.', 'Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike.', 'SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.', 'Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.', 'COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.', 'Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art.', 'Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.', 'Molecular Diagnosis of COVID-19: Challenges and Research Needs.', 'Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development.', 'A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.', 'Molecular Targets in the Chemotherapy of Coronavirus Infection.', 'COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.', 'Perspectives on the development of neutralizing antibodies against SARS-CoV-2.', 'Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises.', 'Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.', 'Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.', 'Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.', 'Convergent antibody responses to SARS-CoV-2 in convalescent individuals.', 'Inactivating Three Interferon Antagonists Attenuates Pathogenesis of an Enteric Coronavirus.', 'A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.', 'Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection.', 'Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold.', 'Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.', 'Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.', 'Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.', 'Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.', 'Broad neutralization of SARS-related viruses by human monoclonal antibodies.', 'COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer.', 'Monoclonal Antibodies for Prevention and Treatment of COVID-19.', 'IL-15 immunotherapy is a viable strategy for COVID-19.', 'Management of COVID-19 Virus Infection by Convalescent Plasma.', 'COVID-19 remedies.', 'Passive antibody therapy in COVID-19.', 'The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.', 'Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.', 'SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract.', 'IgA Summons IgG to Take a Hit at HIV-1.', 'SARS-CoV-2 Infections and Serologic Responses from a Sample of U.S. Navy Service Members - USS Theodore Roosevelt, April 2020.', '', 'Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19.', 'Dissecting antibody-mediated protection against SARS-CoV-2.', 'Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.', 'Challenges in the Production of Convalescent Hyperimmune Plasma in the Age of COVID-19.', 'Neutralizing antibodies mediate virus-immune pathology of COVID-19.', 'An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.', 'The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus Antibodies.', 'Rapid generation of neutralizing antibody responses in COVID-19 patients.', 'A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding.', 'SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area.', 'Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates.', 'Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.', 'Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals.', 'Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.', 'Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model.', 'A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.', 'Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement.', 'Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals.', 'A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition.', 'Structural and functional analysis of a potent sarbecovirus neutralizing antibody.', 'Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual.', 'Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein.', 'Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.', 'Clinical performance of different SARS-CoV-2 IgG antibody tests.', 'Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions.', 'Protective Adaptive Immunity Against Severe Acute Respiratory Syndrome Coronaviruses 2 (SARS-CoV-2) and Implications for Vaccines.', 'Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients.', 'Emergence of novel coronavirus and progress toward treatment and vaccine.', 'Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.', 'Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.', 'Response to Malkovsky.', 'Therapeutic Plasma Exchange-Neutralizing Antibody Combination Therapy for Severe Coronavirus Disease 2019.', 'Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV.', 'Human neutralizing antibodies elicited by SARS-CoV-2 infection.', 'A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.', 'Rapid and robust bioanalytical assays are critical for SARS-CoV-2 therapeutic and vaccine development and beyond.', 'Coronaviruses pandemics: Can neutralizing antibodies help?', 'Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.', 'COVID-19: are neutralizing antibodies neutralizing enough?', 'Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike.', 'Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.', 'Convalescent plasma: A possible treatment protocol for COVID- 19 patients suffering from diabetes or underlying liver diseases.', 'SARS-CoV-2 infection protects against rechallenge in rhesus macaques.', 'DNA vaccine protection against SARS-CoV-2 in rhesus macaques.', 'Audio Interview: Capitalizing on Immune Responses to Covid-19.', 'Immunogenicity of a DNA vaccine candidate for COVID-19.', 'A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).', 'The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection.', 'Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.', \"Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.\", 'Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.', 'Current laboratory diagnostics of coronavirus disease 2019 (COVID-19).', 'Molecular Targets for the Testing of COVID-19.', 'Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?', 'Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.', 'A spike with which to beat COVID-19?', 'Serology assays to manage COVID-19.', 'Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.', 'Identification of Human Single-Domain Antibodies against SARS-CoV-2.', 'Androgen sensitivity gateway to COVID-19 disease severity.', 'Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients.', 'Pathogenesis and transmission of SARS-CoV-2 in golden hamsters.', 'Infection of dogs with SARS-CoV-2.', 'SARS-CoV-2: A New Song Recalls an Old Melody.', 'Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.', 'SARS-CoV-2 immunogenicity at the crossroads.', 'Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak.', 'Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.', 'Recent advances of therapeutic targets and potential drugs of COVID-19.', 'COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions.', 'A Precision Medicine Approach to SARS-CoV-2 Pandemic Management.', 'Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control.', 'Rapid COVID-19 vaccine development.', 'Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays.', 'Perspectives of Immune Therapy in Coronavirus Disease 2019.', 'Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples.', 'Protective humoral immunity in SARS-CoV-2 infected pediatric patients.', 'Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2.', 'Convalescent plasma in Covid-19: Possible mechanisms of action.', 'Development of an inactivated vaccine candidate for SARS-CoV-2.', 'Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.', 'The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections.', 'A human monoclonal antibody blocking SARS-CoV-2 infection.', 'Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development.', 'Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355-359; 2020).', 'The first, holistic immunological model of COVID-19: Implications for prevention, diagnosis, and public health measures.', 'Convalescent plasma transfusion for the treatment of COVID-19: Systematic review.', 'Treatment for emerging viruses: Convalescent plasma and COVID-19.', 'Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.', 'Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.', 'Will antibody tests for the coronavirus really change everything?', 'Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19.', 'Challenges of Convalescent Plasma Therapy on COVID-19.', 'Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.', 'Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic.', 'Evaluate severe acute respiratory syndrome coronavirus 2 infectivity by pseudoviral particles.', 'Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients.', 'Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection.', 'Effectiveness of convalescent plasma therapy in severe COVID-19 patients.', 'Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection.', 'Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.', 'Learning from our immunological history: What can SARS-CoV teach us about SARS-CoV-2?', 'A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV.', 'Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?', 'COVID-19: what has been learned and to be learned about the novel coronavirus disease.', 'Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.', 'The global battle against SARS-CoV-2 and COVID-19.', 'Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.', 'Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.', 'Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.', 'Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?', 'Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility.', 'Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.', 'Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.', 'SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.', 'Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).', 'Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.', 'Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.', 'The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus.', 'Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China.', 'An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies.', 'Adaptive immunity to SARS-CoV-2.', 'Viral Proteins under 70 Kilodaltons in Size Prevent the Development of Long-Lasting B-Cell Immune Memory and IgG2a Prevention in COVID-19 Vaccines.']\n"
     ]
    }
   ],
   "source": [
    "with open('titles_edited.txt') as f:\n",
    "    titles_covab = f.read().splitlines()\n",
    "    \n",
    "with open('search_results.txt') as f:\n",
    "    titles_search = f.read().splitlines()\n",
    "    \n",
    "print(titles_covab)\n",
    "print(titles_search)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3d6d8439",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
